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Magnetic resonance imaging (MRI) has become a powerful clinical modality in 
diagnostic medicine.  It is non-invasive and offers high spatial and temporal resolution.  
The goal of molecular imaging is to reveal the pathophysiology underlying the observed 
anatomy and diagnose diseases.  The detection of pathological biomarkers can lead to 
early recognition of diseases and improved monitoring for recurrence.  Clinically 
available contrast agents are limited in their discrimination of contrast between tissues 
and they tend to have very high detection limits.  Because biomarkers are very low in 
concentration there is a need for high payload deposition of contrast agent (CA) and 
targeted imaging.  Encapsulating discrete Gd3+ chelates in nano assembled capsules 
(NACs) is a simple and effective method of preparing an MRI contrast agent capable of 
delivering a large payload of high relaxivity imaging agent.  The preparation of contrast 
agent containing NACs had previously focused on preparations incorporating GdDOTP5- 
into the internal aggregate.  In this report we demonstrate that other Gd3+ chelates bearing 
overall charges as low as 2- can also be used to prepare NACs.  This discovery opens up 
the possibility of using Gd3+ chelates that have inner-sphere water molecules that could 
further increase the relaxivity enhancement associated with the long rotational correlation 
time (R) that arises from encapsulation.  However, encapsulation of the q = 1 chelate 
GdDTPA2- afforded the same increase in relaxivity as the outer-sphere chelate 
GdTTHA3-.  This leads us to the conclusion that in the NAC interior proton transport is 
not mediated by movement of whole water molecules and the enhanced relaxivity of 
Gd3+ chelate encapsulated within NACs arises primarily from second sphere effects.  The 
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nano assembled capsule platform has been further expanded by an alternative coating 
method, a new cross linked peptidic shell reported in this work affords robust capsules 
and exceptionally high per Gd3+ relaxivities (70.7 mM-1s-1).  The availability of free 
amines on the surface of these capsules can be exploited to attach targeting moieties.  
This was demonstrated through the reaction of fluorescein isothiocyanate (FITC), an 
intense green emitting dye, with these amines.  Green emission from the capsules 
indicated that surface amines were accessible to FITC.  Unlike T1-shortening contrast 
agents, paraCEST agents can be switched on and off by the imaging scientist by turning 
on and off a pre-saturation pulse.  This affords the ability to acquire both pre- and post-
contrast images even after administration of a paraCEST contrast agent.  This could 
potentially eliminate problems co-registering pre- and post-contrast images.  A reverse 
NAC may allow a cationic paraCEST contrast agent to be incorporated in a high payload 
NAC.  We were successful in synthesizing a reverse capsule using DyDOTAM3+, a 
paraCEST agent, and the negatively charged polymer polyacrylate and encapsulated with 
SiO2 nanoparticles. These initial preparations of reverse NACs were not able to generate 
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Chapter 1: Introduction 
1.1 A look back at where we have been and where we are 
Medical imaging has revolutionized medicine, since the discovery of X-rays in 1895 by 
Roentgen1.  Various imaging modalities have been developed which include 
computerized tomography (CT), optical imaging; ultra sound and nuclear imaging (such 
as PET and SPECT) are some of the well-known rapidly growing and frequently used 
medical diagnostic tools.2  X-ray imaging utilizes high frequency characteristics of 
electro-magnetic rays which when passed through human body they are absorbed in 
different amounts depending on the density of the tissue.  Even though the X-rays are 
quick and non-invasive the ionizing radiation has several side effects3, high dose of X-
rays can damage DNA in cells and increases the risk of getting cancer by about 0.08%.  
In the mid-1970s CT came into use; it is an X-ray based technique developed by Godfrey 
Hounsfield.  It is a combination of a computer and X-ray technologies, used to provide 
cross sectional images of the body.  It was Lazaro Spallanzani who started the study 
related to ultra sound in 1794 and Karl Dussik in 1942 introduced ultrasound into the 
field of diagnostics.  It is a medical imaging technique that uses high frequency sound 
waves and their echoes.  It has an advantage of low cost4 and is noninvasive also it does 
not require ionizing radiation5-7, versatile8 and portable9-13.  Ultra sound is mainly used as 
part of routine checkup in case of pregnancy to check fetus in womb.  In the 1950s 
nuclear imaging techniques entered the field of diagnostic imaging test.  Nuclear imaging 
methods employ radioactive tracers which ultimately cause the emission of gamma rays.  
Nuclear imaging is a combined study of physics, chemistry, mathematics, computer 
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science and medicine.  Nuclear imaging commonly used in detecting various infections 
and injuries4.  It is considered a non-invasive technique5.  Positron Emission Tomography 
(PET) and Single Photon Emission Computed Tomography (SPECT) are types of nuclear 
imaging.  In PET the tracer emits a positron when it decays, when the positron collides 
with an electron they mutually annihilate and two gamma rays are simultaneously 
emitted.14, 15  In SPECT radioactive tracer itself emits a gamma ray.  In both cases 
detection of the gamma rays allows an image to be built up.16, 17 The major disadvantage 
of nuclear medicine is the use of radioactive tracers and cost. 
In the 1970s Magnetic Resonance Imaging also evolved.  At first resistive magnets with 
weak magnetic fields were used, producing images with low spatial resolution.  Despite 
this it still had a better soft tissue discrimination than CT allowing earlier diagnosis18.  In 
the late 1980s the super conducting magnets became popular 1.5 Tesla.  MRI has the 
added advantage over X-Ray based CT for not requiring ionizing radiation and MRI has a 
high spatial resolution compared to the other techniques15, 19, it can be used to evaluate 
heart, kidneys, liver, blood vessels20 and other body tissues17.  All the diagnostic 
techniques have now grown from a state of infancy to a high level of maturity. 21 
1.1.1. A history of MRI 
Since William Roentgen first discovered the X-ray phenomenon in 189522 medical 
imaging techniques have become irreplaceable tools in the diagnosis and treatment 
supervision.  Before the development of the imaging modalities the ability to see inside 
the human body historically was to have surgery.  One key advance in the development 
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of modern imaging techniques came in 1822 when the French mathematician and 
physicist Joseph Fourier proposed that a function could be represented by a series of 
sinusoids.  The resulting mathematical transformation, later named Fourier transform, 
forms the basis of Magnetic Resonance Imaging.  A further concrete step towards MRI 
was the Austrian physicist Wolfgancy Pauli’s prediction of the existence of nuclear spin, 
in 1924.  The concept of nuclear spin is central to the development of nuclear magnetic 
resonance methods.  At Columbia University a group led by Isidor Isaac Rabi showed 
that an oscillating magnetic field could be used to induce transitions between nuclear spin 
states of lithium and chlorine atoms in a molecular beam eventually leading to the award 
of a Nobel Prize in physics in 1944.  The extension of Rabi’s 1938 observation of NMR 
in a beam of independent molecules to solid and liquid samples was successfully 
independently and simultaneously in 1948 Felix Bloch23 and Edward Purcell observed 
that signal is emitted from a sample in a magnetic field when it is irradiated with an 
electromagnetic energy of a particular frequency.  They shared the Nobel Prize in physics 
in 1952 for this discovery of condensed phase magnetic resonance.  Although Rabi’s 
work was crucial as the conceptual and technical leap achieved by Bloch and Purcell 
really set the stage for the development of modern NMR and MRI.  Independently Henry 
C Torrey and Erwin L Hahn contributed a final critical component of the modern NMR, 
they demonstrated the feasibility of pulsed NMR, an idea originally suggested by Bloch 
and observed free Larmor precession.  Independently Paul Lauterbur, Raymond 
Damadian and Peter Mansfield introduced methods to allow images of the human body to 
be acquired, including slice selection and fast acquisition.  Research in MRI was largely 
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restricted to academic laboratories during the 1970s.  William Edelstein a post-doctoral 
fellow in Mallard’s group implemented Fourier imaging and obtained the first clinically 
useful image of a human subject.  All demonstrated the imaging potential of NMR and 
MRI was finally born.  In 2003 Lauterbur and Mansfield were awarded Nobel Prize in 
medicine for their development of magnetic resonance imaging.  As a non-invasive 
imaging tool Magnetic Resonance Imaging (MRI) is less harmful than other imaging 
modalities that use ionizing radiation or radioactive tracers, such as X-Rays and PET. 
1.2 Basic principle of Magnetic Resonance 
Magnetic resonance imaging is one of the most widely used techniques in diagnosis, 
clinical medicine and biomedical research.  The basis of MRI is nuclear magnetic 
resonance.  1H is the most favorable nucleus for MRI because of its abundance in biology 
(water), and its high gyromagnetic ratio.  When a human body is placed in a large 
magnetic field the magnetic moments of the proton nuclear spins tend to align slightly 
either with or against the magnetic field (Figure 1.1).  There is a slight predominance of 
nuclei in the lower energy state (slightly more aligned closely with the magnetic field), 
than there are in the high energy state (slightly more aligned against the field).  This 
produces a small net magnetic moment, the magnitude of which can be described by the 








Equation 1: Boltzmann distribution 
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Where ∆E is the energy difference between the two levels and k is the Boltzmann 
constant and T is the temperature in Kelvin. 
 
Figure 1.1: Illustration to represent spins in the absence (left) and presence (right) of a 
strong external magnetic field 
The magnetic dipole moment of a nucleus is directly proportional to the spin angular 
momentum, nuclear spin angular momentum is a fundamental property that makes a 
nucleus a continuously rotating positive charge, and as a moving charge it has an 
associated magnetic field and magnetic dipole moment and the magnetic dipole moment 
is directly proportional to the spin angular momentum.  It is the gyromagnetic ratio that 
relates the nuclear rotating frequency to the strength of the magnetic field.  For hydrogen 
the gyromagnetic ratio is 42.6 MHz / T.  Nuclei of hydrogen contain a single proton 
giving them a net nuclear spin of ½.  Its high gyromagnetic ratio and its high biological 
and isotopic abundance make the proton ideal for MRI.  In the absence of a strong 
external magnetic field individual nuclear magnetic moments are randomly distributed 
and precess incoherently.  However, in a strong external magnetic field a radio frequency 
pulse can be used to apply torque to the net magnetic moment causing coherent 
precession.  The frequency at which the spins precess is called the Larmor frequency () 
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and is given by the product of the gyromagnetic ratio () and the strength of the applied 
magnetic field (B) (Eqn 2).  Gyrometric ratio relates nuclear rotating frequency to the 
strength of the magnetic field and is expressed in terms of MHz per tesla in MRI 
𝜔 = 𝛾𝐵 
Equation 2: Larmor frequency 
Even though individual spins obey the laws of quantum mechanics, the behavior of a 
group of spins experiencing the same magnetic field strength is best described using 
classical mechanics.  Therefore the vector sum of the magnetization vectors from all spin 
packets is represented by a net magnetization M0. 
 
Figure1.2: In the presence of static magnetic field, the spin magnetic moments and the 
resulting bulk magnetization precess at the Lamor frequency around the magnetic field 
At equilibrium the net magnetization vector aligns with the main magnetic field along the 
z-axis.  On applying a radio frequency pulse B1, at or near the Larmor frequency of the 
protons.  The magnetization vector is “tipped” such that component lies in the transverse 
(x-y) plane.  Precession of the net magnetization vector around the z-axis at the Larmor 
frequency induces a current in the receiver coil, which after amplification and processing 
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afford the NMR signal.  This process is independent of the return to equilibrium also 
known as relaxation. 
1.2.1: Inversion recovery pulse sequence 
Inversion recovery pulse sequence is used to measure T1.  It begins with a 180° inverting 
pulse which flips the initial longitudinal magnetization (M0) to point antiparallel the main 
magnetic field B0.  After switching the 180º radio frequency off, the net magnetization 
begins to recover to its equilibrium position.  At a time interval (t) after the 180º pulse a 
90º interrogation pulse is acquired, this rotates the longitudinal magnetization into the x-y 
plane.  This allows the extent of recovery of the longitudinal relaxation to be read out; 
repeating this exercise while varying the value of the time interval t allows a recovery 
curve to be generated from which the longitudinal relaxation time constant, T1, can be 
determined.24  
 
Figure1.3: Representation of the inversion recovery process.  The magnetization vector 
M0 in the equilibrium state. B) Inversion of M0 after 180o pulse. C) Spins precessing in x-
y plane. D) Recovery of the magnetization factor along the z-axis 
1.2.2 Relaxation 
After the radiofrequency pulse is turned off the excited nuclear spins begin to return to 
their original stable equilibrium state.  This process is facilitated by modulating local 
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magnetic fields.  The net magnetization vector M0 gradually returns to lie along the z-axis 
(longitudinal relaxation).  Concurrently there is dephasing (loss of coherence) of the net 
magnetization vector (transverse relaxation).  These two processes are two types of 
relaxation in NMR sometimes called spin-lattice (longitudinal relaxation) and spin-spin 
(transverse relaxation). 
1.2.3: Spin-Lattice relaxation, T1 
Spin lattice relaxation, also called longitudinal relaxation is the recovery of net 
magnetization towards z-axis and involves an exchange of energy between spin systems 
and surrounding or lattice. 
 Rotational and vibrational motion modulates local magnetic fields in the lattice and some 
components of this magnetic field have a frequency equal to the Lamor frequency and 
can therefore facilitate nuclear relaxation.  Relaxation arises from this dipole-dipole 
interactions.  Energy rate loss indicates how closely spins are coupled to the lattice.  
Hydrogen in the form of water is a small molecule so it moves more rapidly, while large 
molecules like fat molecules move much more slowly.  T1 relaxation time shows the 
relationship between the frequency of these molecules and the Lamor frequency.  If these 
frequencies are the same, T1 recovery of Mo is rapid and if they are different the T1 
recovery is slow as a result different tissues exhibit different T1 recovery curves.  Spin-
lattice relaxation is described by an exponential function characterized by a time constant 
T1, the period for the longitudinal magnetization to recover 63% of its equillibrium value.  
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Figure1.4: Principle of magnetic resonance imaging (MRI). A) Spins in the presence of 
external magnetic field. B) Spins precessing in x-y plane at the Larmor frequency upon 
applying a radiofrequency C) Spins decaying to their original z-axis. D) Spins back to 
their original z-axis 
1.2.4: Spin- Spin relaxation, T2 
Transverse relaxation is also called spin-spin relaxation.  After a 90° pulse is applied the 
net magnetization vector is in the transverse plane.  When the radio frequency pulse is 
switched off each individual spins that makes up the net magnetization vector lie in 
transverse plane but they do not all experience exactly the same local magnetic field.  
This means that they will precess at slightly different rates and the population of spins 
begins to dephase or lose phase coherence.  This loss of coherence means that the 
magnitude of the net magnetization vector decreases leading to a loss of signal.  This 
process is also dependent on the rate of molecular motion and so its rate also varies 
between tissues.  Larger macromolecules like in fat experience more static internal 
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magnetic fields and consequently more rapid transverse relaxation.  Spin-spin relaxation 
is described by an exponential decay function characterized by the time constant T2, as 
shown in Figure 1.5. 
 
Figure1.5: Spin-spin relaxation describes the transverse component decay as a function 
of time and is characterized by T2 
 
1.2.5: Relaxivity 
The efficacy of a contrast agent on relaxation is often expressed in terms of relaxivity 
either r1 or r2 to describe the effect on longitudinal and transverse relaxation, 
respectively.  Relaxivity is defined as the relaxation rate constant (either 1/T1 or 1/T2) per 
millimolar concentration of the contrast agent. 
1.3: MRI Pulse sequences  
An MRI pulse sequence is a set of RF pulses applied to a sample to produce a specific 
form of MRI signal.  It is programmed with a set of changing magnetic gradients and 
each sequence has a set of parameters which are described in an MRI protocol.  
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Repetition time (TR) and Echo time (TE) are parameters that are varied to highlight or 
suppress different tissues, reduce imaging times and reduce or avoid artifacts.  There are 
two major sequences in MRI: the spin echo and the gradient echo. 
1.3.1: Spin echo sequence 
In a spin echo sequence, the spins are excited by a 90º pulse.  After a short time a 180° 
radio frequency pulse is applied which reverses the phase of precession causing the 
dephasing magnetization vector to rephrase.  This creates an echo which occurs at the 
echo time TE (TE = 2 × the time between the 90º and 180º pulses).  This helps to reduce 
the effects of magnetic field inhomogeneities.  The magnitude of the echo depends on 
value of T2* which reflects magnetic field homogeneity.  Gradient echo pulse sequences 
differ from the spin echo in that they can use field gradients, rather than a radiofrequency 
pulse, to generate the echo. 
 
Figure1.6: Illustration of pulse sequence diagram for inversion recovery pulse sequence.  
A 180° pulse sequence inversion is applied followed by a 90° recovery pulse, as well as a 
180° repolarization pulse 
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1.3.2: Repetition Time (TR) 
The Repetition Time, TR, determines how much longitudinal magnetization recovers 
between each radio frequency pulse.  It is the time from the application of an excitation 
pulse to the application of the next pulse.  If the repetition time is shorter than the time it 
takes to fully recover longitudinal magnetization returns to its equilibrium position then 
the signal will be attenuated.  The extent of attenuation will depend upon the T1 
relaxation time constant.   
1.3.3: Echo Time (TE) 
The Echo time is time between the application of radio frequency excitation pulse and the 
peak of the echo signal induced by the 180º pulse (Figure 1.6).  An underlying limitation 
of MRI is that measurement of signal is not possible immediately after the application of 
the excitation pulse therefore the signal must be preserved by a refocusing (echo) pulse.  
The magnitude of the echo signal is dependent on the echo time.  The longer the echo 
time the more magnetization is lost unrecoverable to dephasing and the lower the signal. 
Varying the repetition and echo times are the primary means by which image contrast is 
manipulated.  In spin echo sequences there are three main parameters that affect the 
weighting of an image: T1, T2 and proton density. 
1.3.4: T1 weighted images 
Image contrast can be adjusted by varying the repetition time and echo time values.  The 
selection of a short TR will prevent complete recovery of magnetization in tissues with 
shorter T1 relaxation time constants.  A short TE ensures that the maximum 
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magnetization is retained in the transverse plane and the effect of T2 is minimized.  This 
is known as T1.-weighting – it results in image contrast that is more dependent on 
differences in T1 than differences in T2.  The effect of T1 weighting on an MRI of the 
brain can be seen in Figure1.8.  it can be seen for example that fat has a shorter T1 
(because it has a relatively slow tumbling rate which is similar to that of the Larmor 
frequency) and thus appears with stronger signal intensity while water, which has a 
relatively longer T1 (due to relatively high tumbling rate which does not match the 
Larmor frequency), appears with lower signal intensity on T1 weighted MR images. 
 
Figure1.7:T1 contrast difference between water and fat 
1.3.5: T2 weighted images 
If TR is made long then the effect of T1 on image contrast is minimized.  The image can 
be made to reflect differences in T2 between tissues if a longer echo time is selected.  
Longer T2 values mean that more coherent magnetization remains in the transverse plane 
when the echo pulse is applied and this leads to a stronger signal.  A shorter T2 value (e.g. 
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10 - 20 ms)25 causes more loss of coherence and therefore a weaker echo signal.  Images 
acquired with long TR and TE values reflect differences in tissue T2 and are therefore 
known as T2-weighted images.  When selecting a long repetition time and a short echo 
time, the dependence of image contrast on T1 and T2 becomes insubstantial and contrast is 
instead determined by proton density of the tissues. 
 
Figure1.8 : Axial brain MRI image of the same tissue showing how image weighting can 
be used to vary the contrast between grey matter, white matter and cerebrospinal fluid a) 
T1 weighted b) proton density and T2 weighted MRI images26 
 
Figure1.9 :T2 contrast between fat and water 
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1.3.6: Proton density weighted images 
Besides the differences in relaxation times in different tissues, differences in the proton 
density per unit volume can also contribute to contrast in MR images.  Proton density 
images are collected such that the effects of relaxation are minimized: i.e. TE ≪ T2 and 
TR ≫ T1.  Under these circumstances contrast will therefore mainly reflect proton 
density.  Tissues with a high proton concentration will appear bright like brain tissues 
whilst tissues with low hydrogen content will appear dark e.g. cortical bone. 
Table 1: Contrast in spin echo images is determined by the choice of TR and TE times 
Spin Echo imaging Short T2 Long T2 
Short TR T1 weighted - 
Long TR Proton density T2 weighted 
1.4: Imaging with Contrast agents 
Sometimes the inherent contrast in MRI is insufficient for the proper characterization of 
the anatomy or pathology of interest, even after applying appropriate pulse sequences.  In 
these cases, a contrast agent can help amplify the differences between healthy and 
pathological regions.  The major reason of using contrast agents is to increase the 
relaxation rate constant of water protons in the tissue to which it is distributed.  This is 
achieved by use of a paramagnetic element.  Bloch and co-workers reported use of ferric 
nitrate to enhance the relaxation rate constants of water protons and 30 years later 
Lauterbur and co-workers used Mn2+ salts to differentiate water phantoms based on their 
relaxation rate constants.  The fluctuating magnetic field around the paramagnetic center 
of the contrast agent administered due to unpaired electrons is responsible for increasing 
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the relaxation rate constant of nearby water protons.  The relaxivity of a contrast agent is 
a measure of its ability to increase the relaxation rate constant of water.  The relaxivity of 
a contrast agent is described by a model that considers three contributions: the inner 
coordination sphere (which is defined by the exchange of water directly coordinated to 
the metal center); the outer hydration contribution (consisting of water molecules that are 
not directly coordinated to the metal center but are diffusing close to the metal ion); and 
the second hydration sphere (defined by exchange of protons that are weakly associated 
with the chelate but not bound to the metal ion).27  The overall relaxivity is made up from 






Equation 3: Contribution of hydration spheres to overall observed relaxivity 
1.4.1: Inner sphere relaxivity 
 The relaxation arising from exchange of inner sphere water molecules can be described 
by the Solomon- Bloembergen-Morgan (Eqns 4, 5, and 6).  When one or more water 
molecules are coordinated to a paramagnetic metal ion the largest contribution to the 
overall relaxivity comes from these molecules exchanging with the bulk water according 
to Eqn 4.  Currently, all clinically available contrast agents are gadolinium based chelated 









Equation 4: Inner hydration sphere relaxivity 
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q is the number of water molecules which are coordinated to the central metal ion 
(hydration number), C is the molar Gd3+ ion concentration, T1M is the relaxation time 
constant of the bound water protons and 𝜏𝑀 is the mean residence time of the protons 
bound to the water molecules in the inner coordination sphere.  The value T1M, can be 
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                𝑖 =  1,2 
Equation 6: Solomon-Bloembergen-Morgan equations 
CHAPTER 1. Introduction 18 
 
  S is the electron spin quantum number, 𝛾 is the proton nuclear magnetogyric ratio, 
where ωH and ωs are the proton and electron larmor frequency respectively, 𝛽 and g are 
the electronic factor and Bohr magneton, respectively. 𝑟𝐺𝑑𝐻 is the distance between the 
metal ion and the protons of the coordinated water molecules, 𝜏𝑐𝑖 (i = 1, 2) are the 
correlation times of the modulation of dipolar electron-proton coupling, the correlation 
time 𝜏𝑐𝑖 of paramagnetic metal complex reflects weighted contributions from, R, the 
rotational correlation time of the Gd3+ chelate, Tie  the electronic relaxation time of the 
Gd3+ ion and 𝜏𝑀 the mean residence life time. 
1.4.2: Second hydration sphere relaxivity 
Water molecules not directly coordinated to the metal centre may also contribute to a 
relaxation enhancement from the contrast agent.  The second hydration sphere consists of 
water molecules that are weakly asscoiated with the contrast agent.  For example 
hydrogen bonding interactions with the ligand tend to increase the residence time close to 
the paramagnetic ion.  SBM theory also describes the contributiom of second sphere 
relaxivity and the same parameters govern second sphere relaxivity as inner sphere 
relaxivity.  However, unlike the inner sphere water, the number of the second sphere 
water molecules be quite large without decreasing the densicitity of the chelating ligand, 
reducing the chelate’s thermodynamic stability.  The life time of hydrogen bonded water 
molecules in the second sphere can be very short, groups that can increase this life time 
will promote second sphere relaxivity. 
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Figure1.10 : Schematic diagram showing the three hydration spheres, inner sphere 
water molecules are directly bound to the metal center; second sphere consists of water 
molecules coordinated to the ligand of the CA and the outer sphere water molecules 
1.4.3: Outer sphere relaxivity 
The contribution of the outer sphere has been shown to be approximately 1.8 mM-1s-1(20 
MHz, 25℃) of total relaxivity5.  The main determinants of outer sphere relaxivity are the 
relative diffusion coefficient of the dissolved substance and solution (D), the distance of 
closest approach (a) and the electronic relaxation rate constants of the paramagnetic ion.  
The mechanism of outer sphere relaxivity is essentially the same those of the second and 
inner spheres: modulation of dipole-dipole interactions between the electronic spin and 
the proton spin, however in this case the distance are greater and timing is governed by 
the rate of diffusion of the water molecules in close proximity to the paramagnetic centre.  
The diffusion of the paramagnetic chelate in solution is usually described by the Freed 
equations.28, 29  The general form of theory of outersphere relaxivity has similarities with 
the SBM equations as shown in Eqn 7. 







2ℏ2𝑆(𝑆 + 1) 
𝑑3 𝜏𝐷
 
Equation 7: Outer sphere relaxivity Solomon-Bloembergen equations 
Here C is a numerical constant, 𝑁𝑠 is the number of metal ions per cubic centimeter, D is 
the relative translational diffusion time, and 𝛾𝐻 and 𝛾𝑠 are diffusion constants of water 
proton and the metal complex, respectively.  Furthermore, if molecular motion, described 
by the Stokes–Einstein model, is considered then diffusion can be approximated as the 





Equation 8: Einstein model for diffusion for rigid spheres 
For small paramagnetic metal chelates the Freeds equation can be modified as in Eqn 9. 
𝑅𝑜𝑠 =      𝑐𝑜𝑠(
1
𝑎𝐷
)[7J(𝜔𝑠)  +  3J(𝜔𝐻)] 
Equation 9: Freeds equation modification 
For q = 1 systems like GdDOTA1- and GdDTPA2- the overall contribution from the outer 
hydration sphere is 40–50 %30.  Contribution from outer sphere hydration is more 
pronounced in chelates like GdTETA1- and GdTTHA3- (q = 0 chelates), which have no 
inner sphere contribution and relatively small second sphere contributions.  In the case of 
a q = 0 chelate such as GdDOTP5- the outer sphere contibution is close to half of the 
CHAPTER 1. Introduction 21 
 
overall relaxivity, with the remainder arising from a large second sphere contribution 
facilitated by the phosphonates groups coordinated to the paramagnetic centre. 
1.4.4: Contrast agents  
Contrast agents are not directly detected but their effect on the surrounding water 
molecules, in the form of increases to the rate of relaxation that are detected.  Contrast 
agents change the intensity of the water proton signal in appropriately weighted images.  
Gd3+ is the most frequently used paramagnetic ion due to its particularly favorable 
characteristics; the high spin state (seven unpaired electrons) of the 3+ oxidation state and 
the long electronic relaxation time constants, which are much longer (approximately 10-9 
s) than for the other lanthanides such as Dy3+, Ho3+ and Eu3+.31  Unfortunately, free Gd3+ 
ion is toxic in vivo.  The use of Gd3+ in chelate becomes form is therefore mandatory in 
biomedical applications to reduce toxicity and increase solubility of free lanthanide aqua 
ions at physiological pH.  The toxicity of Gd3+ arises due to the comparable ionic radii of 
Gd3+ to Ca2+ which causes the lanthanide to interfere with the Ca2+ signaling channels.32  
Chelation reduces relaxivity since it decreases the number of coordination sites available 
for water proton exchange, from 8-9 sites for aquated Gd3+ ions compared to 1-2 sites for 
Gd3+ chelates.  Clinically available contrast agents (Figure 1.11) tend to have 
comparitively low relaxivity, approximately 4 mM-1s-1 (20 MHz, 25 ºC).  This  is much 
lower than the theoretically predicted maximum,33 assuming that all the parameters that 
affect relaxivity are optimized.  The Gd3+ chelates used in clinical MRI are derived from 
linear and macrocyclic polyaminocarboxylates such as 
DTPA(diethylenetriaminepentaacetic acid), DOTA (1,4,7,10-tetraazacyclododecane-
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1,4,7,10-tetra acetate).34  These chelates have extremely high thermodynamic stability 
constants log 𝐾𝐺𝑑𝐿 = 23.6 and 25.3 for GdDTPA
2- and GdDOTA1-, respectively, in 
addition to retaining one vacant coordination site for an inner sphere water molecule. 
 
Figure1.11 : Contrast agents approved for clinical use, with common name and brand 
They have extremely high Gd3+thermodynamic formation constants log 𝐾𝐺𝑑𝐿 = 23.6 and 
25.3 respectively and a coordination site for an inner sphere water molecule. 
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1.4.5: Parameters that affect relaxivity 
The theory of T1 contrast agents clearly shows that numerous parameters affect relaxivity 
as shown in scheme 1.  The hydration number (q), the rotational correlation time (R) and 
the water residence life time  (M) can all be adjusted by altering the chemical 
environment around the paramagnetic ion.  Altering these parameters can have a 
significant effect on the overal relaxivity value of the chelates. 
 
Scheme 1: Schematic presentation of the factors that affect relaxivity with one inner-
sphere water molecule, R refers to the rotational correlation time of the molecule, m 
mean water residence life time and T1, T2e relaxation times of the Gd3+ electron spin 
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1.4.6: The hydration number (q) 
The hydration number (q) is the number of water molecules that can directly coordinate 
to the paramagnetic metal ion.  The inner sphere relaxation increases linearly with an 
increasing q.  Current clinical contrast agents utilize polyamino-carboxylate chelating 
ligands that bind Gd3+ with a coordination number of eight, leaving one available 
coordination site for the binding of water.  The reason for this is the necessity to balance 
both stability and relaxivity while designing contrast agents.  Although there are new 
chelates being tested which have more than one water molecule coordinated to the metal 
centre.35  There is always an underlying concern over the use of contrast media with 
hydration numbers greater than 1.  Surprisingly, despite possessing no inner sphere water, 
chelates like GdDOTP5- have higher relaxivity than q = 1 chelates like GdDOTA-.  The 
phosphonates groups on GdDOTP5- can interact with an estimated 6 water molecules in 
the second sphere and keep them bound for longer (~ 50 ps) than second sphere waters in 
carboxylate chelates.  For these reasons the contribution of outer sphere hydration more 
than compensates for the absence of an inner hydration sphere.36  
Efforts have been undertaken to increase the number of water molecules directly 
coordinated to the metal centre.  GdDOTA has been modified to increase q = 1 to q = 2 
by removal of an acetate group creating a seven coordinate complex GdDO3A.  The 
relaxivity of GdDO3A is r1 = 4.8 mM-1s-1 (20 MHz, 40℃), under the same conditions 
GdDOTA1- has a relaxivity of 3.5 mM-1s-1.37  The overall difference of relaxivity is 
attributed to an increase in hydration number.  However, this increase in relaxivity comes 
at the cost of a deacrease in the thermodynamic stability constant by three orders of 
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magnitude.38, 39  Ken Raymond and co-workers have devoloped recently a ligand with a 
hydration number of two and rather than traditional poly(amino-carboxylate) complexes 
these ligands are comprised of all oxygen donors and are based on hydroxy pyridinone 
(HOPO) ligands.  Gd-TREN-1-Me-3-2-HOPO is the first such ligand that provides two 
positions for water coordination without compromising thermodynamic stability40. 
1.4.7: Water residence lifetime (𝜏M) 
Water proton exchange is a key factor in governing relaxivity because the relaxation 
effect is transferred to the bulk water protons through water exchange between the 
paramagnetic center and the surrounding bulk water.  However, relaxivity can be limited 
due to water exchange that is either too fast or too slow.  Fast water exchange results in a 
very small water residence life time 𝜏𝑀 of the water molecule coordinated to the 
paramagnetic center which is usually not long enough to allow water to be properly 
relaxed.  Water exchange that is too slow will also result in poor relaxivity due to poor 
transmission of the relaxation effect from the paramagnetic center to the bulk water.  An 
optimal value of 𝜏𝑀 is dependent on magnetic field strength and 𝜏𝑅 of the complex. 
In lanthanide chelates, water can be in exchange occur through an associative or 
dissociative mechanism.  In Gd3+ aqua ion is an eight/nine coordinate system which 
exchanges through an associative pathway.  However, in nine-coordinate mono-hydrated 
exchange can occur only through a dissociative mechanism since there is no availlable 
site for a second water to bind.  Complex charge, solvent accessibility, steric effects 
around the water binding site of chelates are all key factors that govern M.  Negatively 
charged Gd3+ complexes of DOTA or DTPA-like ligands demonstrate shorter residence 
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life time than neutral or positively charged chelates.  M should be short, in the range of 
10 −30 ns, for macromolecular contrast agents at 60 MHz or 1.5 T.  For higher fields a 
𝜏𝑀 in the range of 3-10 ns is predicted to be optimal
41.  The polyaminocarboxylate 
chelates used as clinical contrast agents exchange more slowly than this.  Merbach and 
coworkers increased steric crowding of mono aqua GdDTPA2- and GdDOTA1- chelates 
by substituting one or two of the ethylene bridges with propylene bridges42.  Despite 
having a small effect on the stability of the chelate this induced steric effect on the Gd3+ 
center facilitates the leaving of the bound water, resulting in an increase in water 
exchange rate from about 30-50 fold for GdDOTA1- analogues and 40 -50 fold for 
GdDTPA analogues.  Square antiprismatic (SAP) or twisted square antiprismatic (TSAP) 
isomers observed in Ln (DOTA) complexes and their derivatives have different values.  
Reports display 10–100 times faster water exchange for TSAP isomer when compared to 
SAP.43-46 
1.4.8: Rotational correlation time (R) 
Molecular tumbling usually relates to molecular size.  The relaxvity of a Gd3+ chelate 
increases with increasing R.  The minimum value of R that will afford an increase in 
relaxivity depends on the magnetic field and occurs most efficiently between the Lamour 
frequencies of 10−70 MHz and when M  is between 10−50 ns.  A number of strategies 
have been used to reduce the tumbling rates of contrast agents by covalent or non-
covalent attachment to macromolecules.47 dendrimers, liposomes48, 49 carbohydrates, 
micelles50 and solid nanoparticles.51,52,  Self-assembled Fe[Gd2bpy(DTTA)2(H2O)4]53 
agents displayed four times higher in vivo relaxivity than the commercially available 
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GdDOTA1-.  When the clinical agent MS-325 binds to human serum albumin (HSA) 
using a hydrophobic diphenylcyclohexyl moiety relaxivity increases 8 fold at 20 MHz 
and 37 °C.40, 54 But these approaches have an added advantage of allowing the attachment 
of multiple contrast agents to to be attached to each carrier, further increasing the 
relaxivity both by slow tumbling of the Gd3+ chelate and an increase Gd3+ payload.  The 
binding scheme should be chosen carefully in order to attain the desired  R value without 
affecting the other more favorable properties of the Gd3+ ion complexes, such as the 
water exchange rate 𝜏𝑀   Recently, the model free Lipari- Szabo approach has proved 
useful in describing the rotational motion of macromolecule.  Two kinds of motions are 
assumed to affect relaxation: a rapid, local motion and a slower global motion.  Even 
though it is a crucial parameter, there is no direct method to measure R.  It can be 
obtained by fitting the data from 1H Nuclear Magnetic Relaxation Dispersion (NMRD) 
profile. 
1.4.9: Gd3+ water distance 𝑟𝐺𝑑−𝐻 
T1M is proportional to 1/r6, as shown in Eqn 3 above, therefore varying the Gd3+-water 
distance could lead to drastic enhancement of relaxivity.  Decreasing the distance by 
about 0.2 Å would increase relaxivity by 50%.  Gd-H distances have been  determined by 
X-ray studies or calculated indirectly by relaxivity studies and they are generally in the 
range of 2.5 Å-3.3 Å.  The Gd–H distance for GdDOTA1- and GdDTPA2- derivatives has 
been determined as 3.1 Å ± 0.1 Å by ENDOR spectroscopy.55,56 
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1.5: Electronic relaxation 𝑇𝑖𝑒 
Electronic relaxation for Gd3+ chelates is related to the zero field splitting of the 
electronic spin states and its dynamic distortion.57  In a paramagnetic ion unpaired 
electrons under going relaxation generate a flactuating magnetic field that causes nuclear 
relaxation.58  This defines how efficiently the proton will be relaxed.  For Gd3+ electronic 
relaxation depends on the magnetic field applied and its importance decreases as the 
magnetic field increases .  Gd3+ has a symmetrical electronic configuration and this gives 
rise to relatively slow electronic relaxation but for elements like Dy3+ (even though it has 
a large magnetic moment) it is a a poor relaxation agent since the electronic relaxation is 
fast. 
1.6 Making 𝜏𝑅 longer by encapsulation 
Nano assembled capsules (NACs) are structures in which polyanions and cationic 
polymers are assembled into a stable closed structure encapsulated by a nano-particle 
shell.  It has been shown that GdDOTP5- can be employed as the polyanion in this system 
and be trapped inside the capsule.59  This approach is attractive because formation of 
aggregates occurs at very mild pH values and at room temperature; the nanocapsules self 
assembly technique is extremely facile and quickly produces the nanoassembled 
capsules; the technique is able to effectively slow tumbling of the Gd3+ chelate and 
affords high per-Gd3+ relaxivity.60  NACs have been synthesized using different cationic 
polymers such as polyallylamine hydrochloride (PAH), poly-L-lysine (PLL)61 and 
polyethylenimine (PEI)62 and using multivalent anions such as phosphate citrate63, 
EDTA64, indocyanine green65 and the chelate62 e.g. GdDOTP5-.62  Encapsulation within 
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NACs affords larger gains in relaxivity when compared to the clinically available 
chelates, the method comes with attractive features like the capability to modify the 
surface by attaching targeting molecules on the surface of the nanoassembled capsules.  
In addition it allows for the use of higher payloads of the chelate while at the same time 
reducing molecular tumbling of the small chelates thereby increasing the relaxivity 
values attained.  The per Gd3+-relaxivity was found to be dependent upon the the size of 
the NAC, smaller NACs afforded higher relaxivity.  The size of the NAC can easily be 
manipulated by changing the charge ratio R, which is defined as the ratio of the total 
negative charge of the anion to the total positive charge of the polymer as shown below in 
Eqn 10.62 
𝑹 =





Equation 10: Ratio of anion to polymer 
1.7: Chemical Exchange Saturation Transfer 
Chemical exchange saturation transfer (CEST) is a relatively new method for generating 
image contrast, which holds a great promise in in vivo imaging.  Unlike Gd3+ based MRI 
contrast agents CEST agents require slow water exchange kinetics.  CEST contrast is 
generated by saturating of a pool of solute protons that are in chemical exchange with 
bulk water protons but have a different chemical shift.  Applying a low power radio 
frequency pulse at the resonance frequency of the solute exchangeable pool saturates 
these protons.  Application of a radio frequency pulse B1 that is tuned to the frequency 
offset of the solute proton pool leads to a net excitation of protons in the lower energy 
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states into their higher energy states–this is called saturation.  The number of protons at 
each energy level will equalize and the proton pool will be saturated if the radio 
frequency pulse has enough energy as shown in scheme 2.  The most common pathways 
of chemical exchange for CEST applications include proton molecular exchange, proton 
exchange, or a combination of both.  An example of proton exchange is when a proton 
from an amide group moves to bulk water  and an example of molecular exchange is 
when a water molecule moves between free water and a paramagnetic lanthanide metal 
associated with a paraCEST agents. 
 
Scheme 2:Schematic representation of spins aligned with and against the field (upper 
and lower energy levels, respectively) above simulated NMR spectra (below) for two 
chemically distinct pools of nuclei (left), two spins after a saturation pulse  has been 
applied66 
To observe CEST contrast chemical exchange should be slow to intermediate on the 
NMR time scale 
∆𝜔 ≥ 𝑘𝑒𝑥  
Equation 11: Exchange rate for CEST exchange rates 
Equation11: Exchange regime for CEST 
exchange rates 
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 Systems with longer T1 values allow a larger range of viable exchange rates because the 
longer T1 values allows the spins to maintain their magnetization longer.  In paraCEST 
the shift is due to lanthanide ions and each lanthinde affords a different ∆𝜔.  The large 
chemical shifts afforded by paramagnetic lanthanides allow faster exchange rates while 
mantaining the slow exchange regime between the bound and bulk water molecule.67  
Although  > 2ppm can help avoid direct saturation of water68, larger values of  can 
eliminate this problem completely. 
 
Figure1.12 : CEST spectrum; A CEST effect (or CEST peak) can be observed at 10 ppm 
as highlighted with the arrow. The peak at 0 ppm is due to direct saturation of the bulk 
water protons by the RF saturation pulse.59 
A typical CEST MRI experiment consists of the acquisition of a series of MR images that 
are each preceded by an RF saturation pulse with an incrementally different frequency.  
The normalized MRI signal intensity is then plotted as function of the RF saturation 
pulse frequency offset relative to the bulk water resonance to create a CEST spectrum.  If 
experimental parameters are appropriate then a reduction in MRI signal intensity referred 
to as a ‘CEST peak’ may be observed in the CEST spectrum.  The form of a CEST 
spectrum is shown in Figure 1.12.the CEST peak at 10 ppm is highlighted by an arrow. 
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CEST enables detection of approximately mM proton pools that are in exchange with 
approximately 55 M concentrations of water.  The effects of chemical exchange 
saturation transfer have been investigated for more than 50 years but in the context of 
exogenous images agents for less than two decades.  A modified version of the Bloch 
equations known as the Bloch-McConnell equation that included the CEST effect was 
introduced in 1957.  The earliest example relating directly to CEST imaging was done by 
Forsen and Hoffman in 1963.  They measured hydroxyl proton transfer rates between 
salicylaldehyde and water by placing a saturation pulse on resonance with solute protons 
and recording the solvent signal intensity inorder to study chemical exchange.  It was 
Balaban and Ward in 2000 who coined the term CEST recently when they reported a new 
class of MRI contrast agents that were sensitive to their environment.  They investigated 
applications of CEST agents to measure tissue temperature69 and pH.70-72  Now there are 
many diverse CEST applications including cell labeling73 , monitoring glucose uptake74 
detection of the ischemic penumbra following stroke75, detection of zinc ions76 and many 
more. 
1. 7.1: Diamagnetic CEST agents 
Initially molecules used to generate CEST were diamagnetic molecules known as 
diaCEST agents.  DiaCEST was first reported using small molecules such as barbituric 
acid77 diaCEST agents can be either endogenous or exogenous molecules such as 
macromolecules, sugars, amino acids, glucosaminoglycans and heterocyclic compounds.  
The major drawback of diaCEST agents is the small size of their ∆𝜔.  DiaCEST agents 
typically have  < 6 ppm and this both limits the permitted rates of exchange as well as 
CHAPTER 1. Introduction 33 
 
pre-saturation power (in order to avoid direct off-resonance saturation of water.  
Nonethelees diaCEST agents have been useful for exploring in vivo gene expression, 
imaging the in vivo distribution of glycogen74, 78, pH79, 80 and studying cartilage 
degradation.81  The work on diaCEST has also been fundumental in discovering another 
class of contrast agents known as the paraCEST agents. 
1.7.2: Paramagnetic CEST agents 
Zhang and Sherry were the first to demonstrate that these paramagnetic chelates can be 
used for CEST imaging82.  Initially paraCEST agents developed around paramagnetic 
lanthanide ions.  Lanthanides vary along the 4f period and each metal has a different 
electronic structure and induce different hyperfine shift.  The magnetic moment of the 
lanthnaide influences the magnitude of interaction between external magnetic field and 
magnetic moment.  The magnetic susceptibility governs the lanthanide induced shifts 
(LIS).  These large shifts make paraCEST agents more advantageous than diaCEST 
agents.  These larger LISs () allow faster exchange rates between the exchangable 
protons and bulk water without breaching the slow to intermediate exchange condition.  
This allows more spins to be transferred within a particular time frame, potentially 
increasing CEST.  T1 shortening contrast agents have at least one water molecule 
coordinated to the paramagnetic center but the rate of exchange for these complexes is 
much faster than the slow to intermediate exchange limit which is required for CEST 
agents.  Slower exchange rates have been found for DOTA-tetraamide derivatives, such 
as DOTAM, where the acetate pendant arms have been replaced by acetamide arms.  In 
comparison to carboxylates, amides are weaker electron donors and therefore create a 
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more electron deficient lanthanide center, leading to a stronger water metal interaction.  
This ultimately slows water exchange.83, 84  The amide arms may also provide steric 
hinderance at the metal centre, this may also contribute to a slowing of the exchange of 
exchangable protons.  The DOTAM ligand has been the elementary structure in the 
subsequent synthesis of paraCEST agents85.  Eu3+ of all the lanthanide metals has the 
slowest rate of water exchange and a suitably low paramagnetic relaxation enhancement.  
These are favourable properties in the design of paraCEST agents, an example of such an 
agent is EuDOTAM-gly-Et.86  When Eu3+ is replaced with other lanthanide metals like 
Tm3+~ 50𝑝𝑝𝑚, Dy3+ ~ 70𝑝𝑝𝑚, Tb3+ ~ 60𝑝𝑝𝑚 and Yb3+ ~ 16𝑝𝑝𝑚 and the chemical 
shift from the bulk water changes too, these values depends on the metal chosen.  CEST 
MRI is relatively insensitive (even paraCEST) and often requires high concentration of 
contrast agents.  The CEST efficiency is proportional to the number of exchangeable 
protons resonating at the same frequency per CEST molecule 
1.8 Enhaning sensitivity of CEST agents 
1.8.1: Polymeric systems 
Increasing the number of exchangeable groups on the agent will make a CEST agent 
more sensitive.  This approach to improve CEST sensitivity has been investigated by 
Pikkemaat87 and co-workers.  They studied functionalized YbDOTAM 3+ chelates with 
different generations of dendrimers of poly (propylene imine) and their applicability as 
pH responsive paraCEST agents.  Wu and co-workers took a different approach 
preparing a linear polymer using free radical chain polymerization of EuDOTA-4AmCE 
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derivatives.  The detection limit in both studies were found to be orders of magnitude 
lower than the monomeric agents, but only linearly related to the number of metal ions. 
Thus, one viable approach to increasing the sensitivity of CEST is to increase exchanging 
sites associated with the agent. 
1.8.2: Optimization of the exchange rate 
One of the most important factors that affect CEST efficiency is the exchange rate.  If the 
exchange rate is too fast the exchanging site cannot be activated and if the exchange rate 
is too slow there will be inefficient transfer of saturated spins, both of which will 
decrease the CEST effect.  There is an optimal exchange rate for each exchanging site of 
a CEST agent and this optimal rate has been found to be dependent on the saturation 
power as well as the shift difference .  Higher saturation powers allows one to use fast 
water exchange rate, however for clinical application, the amount of power used is 
limited, and this limits the use of fast water exchanging systems.  Therefore the design of 
CEST agents is focused on slower water exchange rates.  Water exchange rate in 
paraCEST agents can be altered by altering the coordination geometry this depends on 
the type of isomer whether it is a square antiprism (SAP) or a twisted square antiprism 
(TSAP)84, 88 and ionic radii89, 90, changing the lanthanide91 and the chemical environment 
and the chemical environment is the polarity92, 93 and the steric bulky of the side arms94.  
A lot of these parameters have been thoroughly explored in trying to optimize the water 
exchange rate of CEST agents; however, none afford the kinds of gains necessary to 
drive down detection limits to the extent needed for practical in vivo use. 
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1.8.3: Nano systems 
One strategy that has been used to optimize the CEST effect is nano systems, which have 
great promise owing to their high surface to volume ratio.  One of the major strategies 
which have been used to increase the sensitivity of CEST agents is the encapsulation of a 
chemical shift reagent, e.g. TmDOTMA, inside a liposome.  The encapsulated water 
molecule is then shifted away from the bulk water signal.  Two water signals are 
observed on the NMR spectrum for these systems, the intra-liposomal water is shifted 3.1 
ppm downfield from the bulk water.  This intra-liposomal water gives rise to CEST 
because exchange across the phospholipid membrane is slow.  Lanza and co-workers 
incorporated a bifunctional paraCEST agent on the surface of perfluorocarbon 
nanoparticles for molecular imaging; this increased the number of water exchanging 
sites.95, 96  Although, this system provides a large increase in payload and it does not 
compare with the liposome systems since the CEST effect again scales linearly with the 
number of chelates incorporated. 
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Chapter 2.  Nanoassembled Capsules:A Versatile Platform for developing molecular 
imaging agents 
2.1: Introduction 
Magnetic resonance imaging (MRI) has many attributes that make it ideal for molecular 
imaging.  It has high spatial resolution and excellent soft tissue contrast and high 
resolution anatomical images can be obtained without radioactive tracers or ionizing 
radiation.  The difference between the relaxation rate constants of normal and diseased 
tissues can be small and to generate contrast between these tissues contrast agents are 
sometimes used97, 98.  However, the relaxivity of the clinically available contrast agents is 
poor, normally 3-5mM-1s-1 (25 MHz , 25℃)20, 99, 100 and they are non-specific being 
delivered differently to tissue based on diffusion and vascular characteristics.  This means 
that the applications of these contrast agents are limited.  The low detectability arising 
from low relaxivity means that, high doses are often required of Gd3+ chelates (0.1 mmol 
kg-1)101.  This poses a problem for visualization of specific biomarkers of disease by 
molecular imaging, since these biomarkers are present at much lower concentrations 
usually in the micromolar range.  Hence increasing the detectability of MRI contrast 
agents is the key to developing MR based molecular imaging applications.  This can be 
achieved by increasing the relaxivity of the contrast agents by optimizing structural and 
dynamic properties or by increasing the accumulation of contrast agents to the site of 
interest.  Nano assembled capsules (NACs) are one way of achieving both of these goals.  
Wong and co-workers developed a nano encapsulation method in which negatively 
charged nanoparticles, cationic polymers and multivalent anions are combined to 
generate silica/polymer nanocapsules.64, 102, 103  The synthesis of these nanoparticles is a 
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two step method where a cationic polymer and a polyanion104 are added together in 
solution to form an aggregate.  An aqueous suspension of SiO2NPs is added to form a 
shell around the aggregate. 
 
Scheme 3: A Schematic representation of the preparation of nano assembled capsules 
which are SiO2-NP-coated 
The work of Wong and co-workers was extended to the development of contrast agents 
by Plush et al.: NACs were prepared using the polyanionic chelate GdDOTP5- and 
pollyallyl amine hydrochloride (PAH) as the cationic polymer, followed by encapsulation 
with SiO2NPs62.  The encapsulation of GdDOTP5- was found to afford significant 
increases in relaxivity and various synthetic parameters were found to offer good control 
over the size of the NACs produced.  GdDOTP5- relaxivity arises mainly from the second 
sphere of water molecules formed through hydrogen bond interaction between the 
phosphates and the water molecules from the bulk water.105-107  Phosphonates are better 
second hydration sphere generators compared to carboxylates.  For GdTTHA3- the 
contribution is entirely from the outer hydration sphere as a free chelate.  Even though all 
four chelates do have some outer hydration sphere contribution of about 1.8 mM-1s-1 (20 
MHz, 25 ℃)107, 108 to the overall observed relaxivity of the chelates.  GdDOTA1- and 
GdDTPA2- are inner sphere chelates and their primary relaxivity contribution arises from 
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the inner hydration sphere, where the relaxivity arises mainly from the exchange of the 
inner hydration sphere water molecule with the bulk water.  The inner sphere contribution 
to relaxivity is approximately 2.9 mM-1s-1(20 MHz, 25℃).109 hence as free chelate 
GdTTHA3- has a very low relaxivity compared to the other carboxylates.  NAC synthesis 
was performed using the synthesis method which was previously reported62. 
 
Scheme 4: The structures of the chelates investigated in this work16 GdDOTA1-, 
GdDTPA2-, GdTTHA3-, and GdDOTP5- 
Although these results are encouraging, it was unclear to what extent this encapsulation 
strategy can be applied to other chelates, in particular those with charges lower than 5-.  
To do so we investigated the encapsulation with the following chelates GdDOTA1-, 
GdDTPA2-, GdTTHA3-, GdDOTP5- which are, monoionic, diionic, triionic, and 
pentaionic chelates, respectively62.  This choice of chelates also allows another effect to 
be studied: the effect of encapsulating chelates with different hydration states.  
GdDOTP5- chelate which does not contain a coordinated water molecule (q = 0), the 
chelates GdDOTA1- and GdDTPA2- are q = 1 and this could afford higher relaxivity.  The 
idea was to use these negatively charged chelates as salts, to form aggregates with a 
positively charged polymer (PAH) upon mixing and coat this aggregate with silica 
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nanopaticles as the shell material.  Formation of Gd-NACs through self assembly is 
shown in Scheme 3. 
2.2: Experimental 
2.2.1: Materials 
Poly(allylamine hydrochoride),(PAH, 56 000g/mol) ~596 allylamine units per molecule 
were purchased at Sigma Aldrich, collodial SiO2NPs was purchased at Nissan chemicals 
and H8DOTP was purchased from macrocyclics Dallas,TX,USA.  GdDOTA1-, 
GdDTPA2- GdTTHA3-and GdDOTP5-108, 110, 111 were prepared as previously published.112, 
113  The concentration of the chelates was adjusted to a pH of 9 with 1M NaOH.  The 
SiO2NPs solution was diluted to a concentration of 2 wt % by adding 1mL of the 20.3 wt 
% collodial solution in water to 9mL of acetonitrile. 
2.2.2: Synthesis of Nanoassembled capsules 
A (3/2 MeCN/H2O) PAH solution (20𝜇L, 5mg/mL)was mixed with a (3/2 MeCN/H2O) 
Gd3+ solution (120𝜇L) in an eppendorf tube and was vortexed at a low speed.  A turbid 
solution immediately resulted indicating the formation of a polymer-chelate aggregate; 
the aggregates were then aged for 10 minutes.  Diluted SiO2NP suspension (2 wt% in 
MeCN) was added,and the resultant mixture was vortexed at a medium speed.  R charge 
ratios of 0.3, 0.5, 0.75, 1.0, 1.25 were studied in this work.  It is defined as the ratio of 
total number of negative charges from the Gd3+ chelates to the total number of positive 
charges from the polymer as shown in equation 2.1114. 
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R  =  




                         (2.1) 
A turbid solution immediately resulted, indicating the formation of polymer-anion 
aggregate.  The aggregates were aged for 10 minutes before the SiO2NPs suspension was 
added.  The resultant mixture was vortexed at a medium speed.  The precipitate was 
recovered through centrifugation. 
2.3: Characterization 
2.3.1: Dynamic light Scattering  
Hydrodynamic light scattering was carried out with Horiba (Irvine,CA,USA) LB550 
dynamic light scattering instrument. It has an autocorrelator at a laser wavelength of 650 
nm.  All studies were carried out at a 90° scattering angle ,and were temperature 
controlled at 25℃  in polystyrene cuvvetes.  Freshly syringed samples were dispersed in 
water  and measured at four dilutions to ensure size distributions were independent of 
concentration effects.  Samples were regularly agitated to prevent settling of larger 
particles. 
2.3.2: Scanning Electron Microscopy  
SEM was carried out using a FEI, equipped with secondary electron, X-ray (EDX) 
detectors.  Secondary electron images were taken at 5kV with a working distance of 5–10 
mm.  A droplet of NACs suspension was placed on the aluminum stub and dried in air.  
The sample was then sputter coated with gold  for 55 seconds. 
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2.3.3: Relaxometry  
Longitudinal water proton relaxation T1s were measured on a 0.47 T Bruker Biospin 
(Billerica, MA, USA) MiniSpec contrast agent analyzer operating at 19.99 MHz using an 
inversion recovery pulse sequence. NACs were suspended in water (1 mL) at Gd3+ 
concentrations ranging from 0.22 mM to 2.37 mM. Samples were regularly agitated to 
guard against settling of larger particles. Relaxivity values were determined in Excel by 
linear regression analysis of the experimentally determined R1 values as a function of 
Gd3+ concentration. 
2.3.4: ICP-OES Gd3+ concentration determinations 
Concentration determination of Gd was performed using a Perkin Elmer (Waltham, MA, 
USA) Optima 2000 inductively coupled plasma optical emission spectrometer (ICP-
OES). Gd3+ standards were produced by quantitative serial dilution of a commercial 1000 
mgL-1 gadolinium in 2% nitric acid standard (Fluka Analytical) into a 0.1% nitric acid 
solution. Samples were prepared by digesting the dried samples with 70% HNO3 
(100 μL) and water (900 μL). The resulting analyte was vortexed thoroughly, and then 
filtered to remove any particulate using a 0.2 µm filter to produce the final sample for 
ICP-OES analysis. Sample analyte concentrations were calculated to fall in the middle of 
the constructed ICP-OES Gd3+ calibration curve to ensuring, accurate Gd spectral 
readings. Readings were taken in triplicate and averaged. The highest percent relative 
standard deviation allowed between these replicates was 1%, to ensure precise Gd3+ 
spectral readings for the samples analyzed in this work. The concentration of Gd3+ was 
determined for each sample and then multiplied by the dilution factor. 
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2.4: Results and Discussion 
The size of the NAC and per Gd3+ relaxivity were found to be inversely related.  For the 
benefit of our research it was desirable to keep certain synthetic variables, such as solvent 
and cationic polymer, fixed.  The effect of varying the polymer used for aggregate 
formation has already been explored by Plush and co-workers.62  The nature of the 
polymer was found to have an effect on the size of the NACs attained and polly allyl 
hydrochloride amine was found to give smaller NACs compared to the other polymers 
studied.  Smaller NACs afforded higher per Gd3+ relaxivities, therefore for this work only 
PAH was used for NAC synthesis.  In all experiments in this chapter the solvent mixture 
used was 3:2 v/v aetonitrile and water mixture.  Stock solutions of the chelate Gd3+and 
polymer were prepared in 3:2 v/v of acetonitrile and water.  In all cases, upon addition of 
the anionic chelate the solution became turbid except for cases in which the anion was 
GdDOTA1-. The reaction were stirred vigorously for 15 seconds, the aggregate was aged 
for ten minutes, and then SiO2 nanoparticles in 100% acetonitrile was added.  The 
addition of SiO2 nanoparticles as the aggregate coating was crucial because the SiO2 
nanoparticles stabilize the polymer chelate aggregate.  To ensure that there was no 
distortion on the relaxivity measurements by any non-encapsulated Gd3+ chelates the 
NACs were put through a series of centrifuge cycle washes in 10 kDa MWCO centrifugal 
filter units.  The constitution of the 2 wt % SiO2 nanoparticles stock suspension was 
found to be critical to the formation of NACs; if the SiO2 nanoparticles were suspended 
in water alone, or a 3:2 v/v MeCN/H2O mixture, then NAC formation was not observed.  
NACs were characterized using dynamic light scattering for size analysis.  It was 
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observed that as the charge ratio R increased the average size of the NACs was observed 
to increase independent of the chelate being studied.   
 
Figure 2.13: The effect of changing the R value on the average hydrodynamic diameter 
of the NACs produced for GdDTPA2- (purple), GdTTHA3- (red) and GdDOTP5- (green). 
Dashed lines are a guide to the eye only; error bars represent the 1st standard deviation 
of the size distribution of the capsules. Sizes and their distributions are the average of 6 
NAC preparations115 
There was no general relationship between the size of the NACs and the charge ratio 
observed across all the three chelates studied.  The size of NACs encapsulating 
GdDTPA2- and GdDOTP5- was observed to increase sublinearly with increasing R value 
even though structural relationship is not identical between these two chelates.  In 
contrast, for NACs encapsulating GdTTHA3- the size of NACs seemed to increase 
superlinearly with increasing R (Figure 2.13).  On a structural basis, this observation is 
difficult to explain. The only notable difference in structure is that GdTTHA3- unlike 
GdDTPA2- and GdDOTP5- it has one uncoordinated carboxylate.  So, one possible 
explanation is that while the charge on GdDTPA2- and GdDOTP5- is well distributed on 
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the chelate, part of the charge on GdTTHA3- is concentrated on one of the carboxylates; 
this may alter the interaction of the chelate and the cationic polymer.. 
 
 
Figure 2.14: SEM images of NAC preparations in 3:2 v/v MeCN/H2O with PAH and: A) 
GdDOTA1- R = 1.0; B) GdDTPA2- R = 0.75; C) GdTTHA3- R = 0.75; D) GdDOTP5- R = 
0.75 
The production of NACs was apparent from the SEM images on Figure 2.14 of capsules 
which have been shown to withstand several rounds of centrifuge without losing its 
structural integrity.  GdDTPA2-, GdTTHA3- and GdDOTP5- are capable of forming 
aggregates with the polymer in a way that will allow NAC formation.  Furthermore, the 
monoionic GdDOTA1- appears incapable of aggregation in a manner that allows NAC 
formation.  It was shown by Wong and co-workers that monovalent acetate could not 
ionically cross link polymer chains, this was confirmed by Monte Carlo simulations, 
where higher valent salt caused polymer to be in a collapsed or condensed form114, 116 
hence increasing the ability of the polymer to cross link with the multivalent anion.  The 
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incorporation extent of Gd3+ chelate was determined using ICP-OES were the NACs 
were digested using 15.7 M nitric acid.  The concentration of Gd3+ was measured in both 
the supernatant and the NAC.  Overall there was greater than 99% incorporation of the 
Gd3+ chelates achieved for NACs from all the chelates, though a lower percentage value 
was observed for chelates like GdDTPA2- which had >93% incooperation as shown in 
table 2 , For GdDOTA1- no further studies were performed because there was no 
consistency in the formation of NACs.  The per Gd3+ relaxivity was calculated using the 
regression analysis by plotting the longitundal relaxation rate constant (determined by 
inversion recovery) against the concentration of the Gd3+: the gradient is the relaxivity.  
The effect of changing the R value on the per Gd3+ relaxivity is shown in Figure 2.15.  
These results are braodly similar to those observed previously with GdDOTP5- and PAH 
NACs in a different solvent mixture: as the R value is increased the per-Gd3+ relaxivity 
decreases.  In all cases the smaller the NAC size the higher the per Gd3+ relaxivity 
observed.62 
In comparison the GdDTPA2- continaing NACs have a lower relaxivity of the same R 
value (0.3), even though it is a q = 1 chelate.  Hence, it seems that the contribution of the 
inner hydration sphere seem to be masked upon encapsulation.  Encapsulation of q = 1 
chelate did not seem to have an effect on relaxivity as was suggested in comparison to the 
effect it had on q = 0 chelates and GdDOTA1- of a lower valence 1 could not afford to 
form aggregates with the polymer therefore no further studies were perfomed on 
GdDOTA1-.  Encapsulation of chelates do have an effect on the overall relaxivity attained 
by these chelates in comparison to the relaxivity of free chelates, NACs had higher 
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relaxivity values even for larger capsules which had lower relaxivity values, they still 
attained higher or equal relaxivity values compared to the free chelates as shown in Fig 
2.13. 
 
Figure 2.15: The effect of changes in the overall Gd3+ chelate charge on the relaxivity of 
the NACs produced for different R values 
 
Figure 2.16: Relaxivity values measured at 0.47 T at 25 ° C of encapsulated Gd chelates 
compared to the relaxivity values of the free chelates 
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Table 2: Summary of the variations in size and relaxivity arising from changing the 
chelate charge and R value during the preparation of NACs. 
Chelate R value % Gd3+ incorpa Diameter nmb 𝒓𝟏 mM
-1s-1 c 
GdDTPA2- 0.30 99.7 127 ± 58 23.3 ± 0.3 
 0.5 94.5 645 ± 267 14.9 ± 0.1 
 0.75 93.3 1088 ± 232 8.5 ± 0.05 
 1.0 99.0 1542 ± 465 7.8 ± 0.01 
 1.25 99.9 1802 ± 581 4.8 ± 0.1 
GdTTHA3- 0.3 99.6 105 ± 60 22.7 ± 0.1 
 0.5 99.9 180 ± 110 14.0 ± 0.1 
 0.75 99.9 370 ± 260 7.4 ± 0.3 
 1.0 99.0 1100 ± 500 7.1 ± 0.3 
 1.25 99.9 1651 ± 445 6.5 ± 0.1 
GdDOTP5- 0.3 99.9 320 ± 260 46.4 ± 0.3 
 0.5 99.1 620 ± 235 19.8 ± 0.1 
 0.75 98.9 1147 ± 368 15.8± 0.1 
 1.0 98.6 1232 ± 650 7.1 ± 0.1 
 1.25 99.5 1598 ± 401 6.3 ± 0.2 
1. a The percentage of Gd3+ chelate added to the NAC synthesis that was found to be incorporated 
into the NAC. 
2. bThe mean average hydrodynamic diameter of 6 NAC preparations ± the 1st standard deviation of 
the size distribution, determined by dynamic light scattering. 
3. c The mean longitudinal relaxivity of 6 NAC preparations ± the 1st standard deviation, determined 
at 20 MHz and 25 °C.115 
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The relaxivity attained using highest R charge ratios, which produced large NACs, was 
much lower and was independent of the chelate used to synthesize the NACs.  In 
comparison to the NACs containing carboxylates chelates (GdDTPA2- and GdTTHA3-), 
the NACs containing GdDOTP5- had a substantially higher relaxivity compared to the 
slightly smaller NACs produced from the carboxylates containing chelates.  This is 
probably due to the known promotion of the strong second sphere interaction of the water 
molecules with the water molecules from the bulk water and the phosphonate groups of 
GdDOTP5- more than the carboxylates groups this tend to compensate the contribution 
from the inner hydration sphere hence GdDOTP5- attained higher relaxivity.  
Encapsulation has effectively reduced the molecular tumbling of these chelates and the 
water molecules tend to be bound in the second sphere increasing water exchange rate 
and reducing 𝑟𝐺𝑑𝐻.  Increasing the distance of the water molecule to the metal centre 
from the inner hydration sphere has a major effect on relaxivity given that the rotational 
correlation time is reduced.  Upon encapsulation of the carboxylate chelates GdDTPA2- 
the exchange of inner sphere water molecules is extremely slow or the exchange is so 
insignificant that its contribution to overall relaxivity attained is not observed, hence the 
overall contribution of the inner hydration sphere relaxivity on GdDTPA2- does not show 
in its relaxivity which is similar to that of GdTTHA3- a chelate without a coordinated 
water molecule.  For these reasons encapsulation has a greater effect on the relaxivity of 
GdTTHA3- than that of GdDTPA2-.  GdTTHA3- has a relaxivity of just 2.65 mM-1s-1 as a 
free chelate arising primarily from an outer sphere contribution,35 but showed 
approximately 8.6 times increase in relaxivity for R = 0.3 NACs (Figure 2.16).  This 
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increase in relaxivity of GdTTHA3- could be attributed to a magnification of the second 
sphere effect upon encapsulation of GdTTHA3-therefore an abrupt increase in relaxivity 
was observed for this chelate relaxivity.  We speculate that inside the NAC water is 
comparativiely scarce and therefore water in the inner hydration sphere of GdDTPA2- is 
unable to freely exchange and this mechanism contributes  insignificantly to the overall 
relaxivity.  Proton exchange113 may be a more important mechanism for the transfer of 
relaxation from the chelate to the bulk rather than the whole water molecule diffusing 
between the bulk water and NAC interior. 
2.5: Conclusions 
In conclusion, encapsulation of Gd3+ chelates is a robust and versatile method to 
synthesize high payloads of contrast agents, and attain very high relaxivity values without 
expensive modification to the contrast agents.  Lower charge densities like 2- were well 
tolerated in the synthesis of NACs, they formed capsules for all the R values studied in 
this chapter but charge of -1 could not form a consistency formation of capsules.  As was 
shown by Wong and co-workers that monovalency acetate could not ionically cross link 
polymer chains, this was confirmed by Monte Carlo simulations, where higher valent salt 
caused polymer to be in a collapsed form hence better interaction with the polymer.  
Therefore a dependence on charge was observed the lower the charge of the chelate the 
less the interaction of the chelate with the polymer because for lower charge density, less 
turbid solution were observed for the chelate GdDTPA2- compared to the turbidity 
observed for GdDOTP5-of the same charge ratio, therefore charge do have an effect on 
the formation of the aggregate.  The ability of a chelate to form an aggregate with the 
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polymer has a profound effect on the rigidity attained to reduce molecular tumbling on 
the chelate hence higher charge density tend to have a better interaction with the polymer 
hence better rigidity attained by higher charges compared to lower charges as was shown 
by the relaxivity values attained by smaller capsules which have better interaction with 
the polymer on forming the aggregate hence better reduction in molecular tumbling in 
solution of the small chelates.  Size of the NACs was affected by the R value and cation 
employed, there was a general trend that the smaller the R value the smaller the size of 
the NACs produced.  Encapsulation of GdDTPA2- a q = 1 chelate did not show to 
enhance the relaxivity attained by this chelate, GdDOTP5- and GdTTHA3- q = 0 chelates 
had very competetive relaxivity values, which we speculated that this could be that upon 
encapsulation the contribution from the inner hydration sphere becomes scarce therefore 
its effect is not observed in the per Gd3+ relaxivity attained from the q = 1 chelates.  In 
this work we observed that the smaller the NAC the better the restriction in tumbling of 
the chelates hence higher per Gd3+ relaxivity for smaller NACs compared to their larger 
counterparts.  Encapsulation of Gd3+ chelates allows high payload delivery of these 
chelates and therefore an increase in relaxivity especially for targeted MR imaging where 
T2-shortening iron oxide contrast agents are used at lower concentrations.  This work 
shows that encapsulation of Gd3+ chelates increases relaxivity values by reducing 
molecular tumbling and can also deliver high payloads of the imaging agent this may 
decrease limits of detection to levels at which biomarkers for disease pathology exist.  .  
In addition to slowing the tumbling of the chelates by forming an aggregate with the 
polymer, when designing a contrast agent for MRI one must ensure that water molecules 
associated with the NAC have access to bulk water as this is critical to the function of an 
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MRI contrast agent.  For this reason making smaller NACs is crucial for achieving the 
highest per-Gd3+ relaxivity.  In these smaller NACs encapsulation allows sufficient 
movement of water protons to allow an enhancement in relaxivity for all chelates. Annah 
is the coolest ever!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!
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Chapter 3.  An Alternative Coating Method for the High Payload Synthesis of Nano 
Capsule MRI Contrast Agents 
3.1.1 Introduction 
We have demonstrated that NACs represent a versatile and robust platform that may 
allow the dvelopment of targeted MRI contrast agents for molecular imaging applications 
with very low detection limits.  However, concern must remain about the in vivo stability 
of these capsules with their shells that are held togather solely by electrostatic forces.  
One possible solution to this problem may be the use of capsules that also contain a high 
payload of a Gd3+ chelate encapsulated within a covalently linked shell.  Capsules should 
incorporate as many contrast agents as possible into a single capsule to facilitate the 
delivery of large payloads to a pathology of interest in targeted imaging applications. 
Stucky and co-workers reported the same synthesis approach.117  These spheres are called 
nano-assembled capsules (NACs).  The synthesis of NACs is rapid and it occurs under 
ambient conditions at mild pH values.62  Synthesis method of NACs have been used to 
encapsulate a clinical florescent probe indocyane green102 and GdDOTP5-62 an MR 
contrast agent and had a significant enhancement on relaxivity of GdDOTP5-.  In another 
work we published a series of Gd3+ chelates where encapsulated in these capsules and 
there was a significant increase in relaxivity of these chelates, attaining relaxivity value 
of 46.3 mM-1s-1 for chelates of GdDOTP5- R = 0.3 which is ten times more than the 
relaxivity value of the free chelate.115  The NAC synthesis method has advantages 
compared to other synthetic methods of increasing a high payload of metal centres 
because it is performed at room temperature and is synthetically straight forward.  The 
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polyanionic Gd3+ chelates are mixed with a solution of a polymer in a mixture of a 
organic/aqueous solution and forms an aggregate which is encapsulated with an SiO2NPs 
to form a NAC.  The formation of NACs is driven by the electrostatic attraction of the 
ions involed.  Due to this ectrostatic attraction this tends to raise questions on how robust 
these NACs are in vivo, hence need to devise another route to synthesize an alternative 
coating method.  A new encapsulation method was employed  which uses peptidic 
linking to form the capsule shell.  Herein we describe the development of Crosslinked 
Assembled Capsules (CACs) that are prepared firstly by mixing the polymer solution and 
a poly anion to form an aggregate in the same manner as for NACs.  The surface of the 
aggregate is covered with primary amines which could be used to form peptidic bonds 
with a dicarboxylic acid, such as succinic acid,to coat and crosslink the surface with a 
peptide coupling reagent (EDC).  This encapsulation method used was investigated with 
a view to produce CACs encapsulating GdDOTP5-.  The initial stage of synthesis of this 
work was performed using PAH and pyrophosphate solutions and glutamic acid was used 
to coat the aggregate and EDC for cross linking. 
3.1.2 Experimental 
Water refers to deionized water with a resistivity of 18.2 M.  All solvents and reagents 
were purchased from commercial sources and used as received unless otherwise stated.  
Pollyallylamine hydrochloride (PAH) (56,000 MW), poly-L-lysine (50,000 MW), L-
glutamic acid, succinic acid and 1-ethyl-3-(3-dimethylaminopropyl) carbodiimide (EDC) 
were purchased from the Sigma-Aldrich corporation and used as received.  H8DOTP was 
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purchased from Macrocyclics. GdDOTP5- was synthesized by previously reported 
methods.108, 110, 118.  
 
Scheme 5: Schematic of synthesis of cross linked assembled capsules versus that of 
NACs 
3.1.3 Synthesis of CACs with Simple Diamagnetic Anions 
Stock solutions of polymer and anion were prepared in 100% water at pH 9.  Stock 
solution concentrations were as follows: (polymer) = 89 µM, (citrate) = 4.2 to 19.9 M and 
(pyrophosphate) = 2.9 to 14.9 M.  The polymer (20 μL) and anion (120 μL) stock 
solutions were then added to water (10 mL) at pH 9.  The charge ratio R was varied by 
varying the initial concentration of anion.  After mixing the reaction immediately became 
turbid reflecting the formation of a polymer-anion aggregate.  The solution was vortexed 
at low speed for 10 s and then aged for 3 minutes without agitation.  After aging, a 
solution of dicarboxylic acid (20 μL, 0.089 M) was added.  Succinic acid or L-glutamic 
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acid were used at identical concentrations.  The solution was gently mixed and then aged 
for 3 minutes.  A solution of 1-ethyl-3-(3-dimethylaminopropyl carbodiimide (20 µl, 
0.174 M) in H2O was then added, gently mixed and aged for 30 minutes.  The reaction 
was then gently centrifuged, the supernatant removed and the capsules recovered by 
resuspension in water. 
3.1.4 Synthesis of Gd3+-containing CACs 
An 8.9 µM stock solution of PAH was prepared by dissolving PAH (0.0498 g, 0.89 
µmol) in a 3:2 v/v mixture of acetonitrile and water (10 mL).  A stock solution of 
GdDOTP5- was prepared by diluting a concentrated solution into a 3:2 v/v mixture of 
acetonitrile and water to afford a 0.757 mM stock solution.  The pH of the chelate stock 
solution was adjusted to 9, by addition of 1M NaOH solution.  Stock solutions of EDC 
(0.174 M) and succinic acid (0.089 M) were prepared in pure water.  For CACs R = 0.5, 
stock solutions of the polymer (20 µL) and GdDOTP5- (120 µL) were added to a stirred 
solution of 3:2 v/v MeCN/H2O (1 mL).  Upon addition of the chelate stock solution the 
reaction rapidly became turbid.  The reaction was vortexed at a medium speed for 10 
seconds.  Aggregates were then allowed to age for 3 minutes before addition of the 
succinic acid stock solution (20 µL).  The reaction was vortexed for a further 10 seconds 
at medium speed and then allowed to age without agitation for 3 minutes.  A solution of 
EDC (20 µL) was added and the reaction was aged for 1 hour.  Unreacted starting 
materials were removed by filter centrifugation using 10 kDa MWCO filter centrifuge 
tube.  The CACs retained in the filter centrifuged tube were washed with water and 
filtered by centrifugation for 30 minutes at 9,000 rpm a total of six times.  The CACs 
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were then taken up into water (1 mL) and recovered into a sample vial.  All CAC 
preparations were repeated six times and data are an average of all of these independent 
capsule preparations. 
3.1.5 Scanning Electron Microscopy 
Scanning electron microscopy (SEM) was performed on a FEI Sirion FEG electron 
microscope equipped with an energy dispersive X-ray (EDX) detector.  A droplet of 
NACs suspension was placed on the aluminium stub and dried in air, the sample was then 
sputter coated with gold for 55 seconds.  Secondary electron images were taken at 5kV 
with a working distance between 5-10mm. 
3.1.6 Transmission Electron Microscopy 
Transmission electron microscopy (TEM) imaging was performed using carbon/copper 
TEM grids on a JEOL 1200 EX system with an accelerating voltage of 40 to 120 kV and 
mounted with a Sis Morada 11 Mpixel CCD camera. 
3.1.7 Confocal microscopy 
Confocal images were captured using a TCS-SPE II Leica DM 2500 with 63X 
magnification and a laser excitation wavelength of 488 nm for FITC an excitation 
wavelength of 500 nm and emission wavelength 555nm.  Scan format was 512 X 512 
pixels.  Samples were mounted on conventional glass slides and sealed under cover slip 
to prevent drying 
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3.1.8 Light Scattering 
Dynamic light scattering was performed on a Horiba LB-550 dynamic light scattering 
instrument.  For these measurements freshly syringed filtered samples were dispersed in 
water and measured at four dilutions to ensure size distributions were independent of 
concentration effects.  Samples were regularly agitated to guard against settling of larger 
particles. 
3.1.9 Relaxometry 
Water proton T1s were measured on a 0.47 T Bruker MiniSpec contrast agent analyzer 
operating at 19.99 MHz using an inversion recovery pulse sequence.  NACs were 
suspended in water (1 mL) at Gd3+ concentrations ranging from 0.22mM to 2.37 mM.  
Samples were regularly agitated to guard against settling of larger particles.  Relaxivity 
values were determined by linear regression analysis of the experimentally determined R1 
values as a function of Gd3+ concentration in Excel. 
3.1.10 ICP-OES Gd3+ Concentration Determinations 
Concentration determination of Gd was performed using a Perkin Elmer Optima 2000 
inductively coupled plasma optical emission spectrometer (ICP-OES).  Gd3+ standards 
were produced by quantitative serial dilution of a commercial 1000 mgL-1 gadolinium in 
2 % nitric acid standard (Fluka Analytical) into a 0.1% nitric acid solution.  Samples 
were prepared by digesting the dried samples with 70% HNO3 (100 µL) and water (900 
µL). The resulting analyte was vortexed thoroughly, and then   filtered to remove any 
particulate using a 0.2µm filter to produce the final sample for ICP-OES analysis.  
Sample analyte concentrations were calculated to fall in the middle of the constructed 
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ICP-OES Gd3+ calibration curve to ensure accurate Gd spectral readings.  Readings were 
taken in triplicate and averaged.  The highest percent relative standard deviation allowed 
between these replicates was 1%, to ensure precise Gd3+ spectral readings for the samples 
analyzed in this work.  The concentration of Gd3+ was determined for each sample and 
then multiplied by the dilution factor. 
3.1.11 Results and Discussions 
The first step of the CAC preparation is identical to that of NACs.  An initial preparation 
of CACs was performed using pyrophosphate as anion and PAH as the cationic polymer 
to form an aggregate in pure water at a mild pH by Sally Plush.  L-Glutamic acid was 
then used to create a coating of the surface of the aggregate, interacting with the free 
amino groups that are available on the aggregate surface.  The coated aggregates were 
then crosslinked by addition of a peptide coupling reagent 1- ethyl-3-(3-dimethylamino 
propyl) carbodiimide (EDC).  Capsules were purified by centrifugation and resuspendend 
in water.  TEM images show the presence of the capsules as shown in Figure 3.17.  This 
new approach to encapsulation was investigated in terms of its ability to encapsulate Gd3+ 
chelates.  The same methodology was employed to encapsulate GdDOTP5-, which was 
mixed with PAH (the cationic polymer) in 3:2 MeCN/H2O at pH 9.  R ratios from 0.3 to 
1.0 where investigated and in each case a turbid solution rapidly formed a sign of the 
formation of an aggregate.  Succinic acid was used as the coating dicarboxylic acid on the 
surface of the aggregate.  EDC was used, as before, as the cross linker. After purification 
by centrifugation through a 10kD MWCO centrifuge filter Gd3+-containing CACs were 
obtained.  Formation of CACs is shown on the SEM images Figure 3.17. 
CHAPTER 3. Alterative Coating Methods for Nano-Capsule Contrast Agents 60 
 
Figure 3.17: Electron micrographs of different stages of CAC preparation.  A) TEM 
image of a single pyrophosphate/PAH aggregate (R = 5) showing the loose morphology 
of the aggregate; B) TEM image of a pyrophosphate/PAH aggregate with a glutamate 
coating showing the tighter surface morphology of the coated aggregate; C) TEM image 
of a pyrophosphate/PAH CAC after treatment with EDC showing the crosslinked capsule 
shell; and SEM images of GdDOTP5-/PAH CACs after treatment with succinic acid and 
EDC D) R =0.5 and E) R = 1. 
The hydrodynamic diameter of the CACs was determined by dynamic light scattering.  
The size of CACs was found to be dependent on the charge ratio R in a similar way to 
NACs: the smaller the R value the smaller the CACs observed and vice versa. 
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Figure 3.18: A comparison of CACs (red) and NACs (green) prepared using PAH and 
GdDOTP5- average diameter. Each value is the mean of six nano capsule preparations 
 
Figure 3.19: A comparison of CACs (red) and NACs (green) prepared using PAH and 
GdDOTP5- contrasting the per Gd3+ longitudinal relaxivity (20 MHz and 298 K). Each 
value is the mean of six nano-capsule preparations 
 
The smallest capsules were attained (R = 0.3) from this method were almost half the size 
of the NACs produced using the same value of R and chelate (GdDOTP5-) as shown in 
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Figure 3.18.  It is notable that the trend for the size of NACs and CACs observed as R 
changes is not identical, although CACs are smaller than NACs when prepared with low 
R values they are slightly larger than NACs when higher R values are employed. 
The smaller size of R = 0.3 CACs versus NACs has a substantial impact on relaxivity.  
The measured relaxivity, 70.2 mM-1s-1 (20 MHz, 25 C) represents an almost 2-fold 
enhancement in relaxivity over the NACs (Figure 3.19) and a 15-fold enhancement over 
GdDOPT5- alone. In all cases the per Gd3+ relaxivity correlated with the size of the 
capsule formed; as the charge ratio increases there was a decrease in relaxivity and an 
increase in size of capsules (Figure 3.19).  The larger the capsule size the longer the 
distance the proton close to the chelate has to diffuse to exchange with bulk water.  The 
higher relaxivity values found for CACs relative to NACs, even in the case of R = 1.0 (in 
which the CAC is larger than the NAC) is an indication that the cross-linked coating of 
CACs is and least as, and probably more, permeable to water than the SiO2NP shell of 
NACs.  Interaction of the GdDOTP5- with the cationic polymer PAH in the aggregate is 
anticipated to limit the tumbling of the chelates in solution; this is the cause of the large 
increase in overall relaxivity.  Smaller capsules have higher relaxivity compared to larger 
capsules because proton (or whole water) exchange between the chelate and bulk water is 
faster (diffusion being proportional to the reciprocal of the diameter).  GdDOTP5- 
aggregated into larger capsules do not have such high relaxivity values which shows that 
encapsulation does play a role in limiting diffusion of water proton even though a robust 
shell for encapsulating is needed if these nano assembled capsules are to be used in vivo. 
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Table 3: The average hydrodynamic diameter (m) determined by dynamic light 
scattering of GdDOTP5- containing nano capsules (CACs and NACs) prepared with PAH 
in 3:2 MeCN/H2O as a function of the R value used in their preparation.  Data are 
presented with the 1st population standard deviation 
 
CACs NACs % Gd incorp 
R = 0.3 0.127 ± 0.057 0.32 ± 0.26 99.2 
R = 0.5 0.265 ± 0.138 0.62 ± 0.235 98.7 
R = 0.75 0.863 ±0.488 1.147 ± 0.368 98.6 
R = 1.0 1.534 ± 0.58 1.232 ± 0.65 99.5 
The percentage encapsulation of GdDOTP5- into CACs was found to be ≥ 98%, 
comparable to the rate of incorporation into NACs.  The high rate of incooperation of 
GdDOTP5- into these capsules is correlated to the efficient interaction of GdDOTP5- with 
the polymer PAH which in turn afford high payloads of the chelate per capsule.  
3.1.12: Probing the stability of cross linked assembled capsules (CACs) 
A synthesis method has been developed to synthesize nano-scale capsules loaded with 
high payloads of high relaxivity MRI contrast agent.  The cross-linked encapsulating 
shell of these capsules affords the promise of high stability and robustness, rendering the 
capsules more appropriate for in vivo applications.  To test this resilience of CACs to 
different pH regimes and metal ion concentration was examined.  Suspensions of CACs 
were incubated at pH 3, 5, 7, 9 and 11 and in the presence of 5 mM CaCl2 and 5 mM 
MgCl2 and 200 mM NaCl.  These values exceed the range of pH and metal ion 
concentration found in physiological fluids.  In addition to the long term stability of the 
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CACs, the effect of metal ions on relaxivity was also of interest, since both Ca2+ and 
Mg2+ are known to bind to GdDOTP5-, quenching relaxivity.  The CACs were analyzed 
in terms of their size (DLS), relaxivity (T1 relaxometry) and morphology (SEM). 
 3.1.13: The effect of pH on CAC Stability 
The structure of cross linked assembled capsules is held together by the peptidic bonds of 
the encapsulating shell.  It is reasonable to expect that these bonds and the electrostatic 
interactions in the CAC interior may be disrupted by changes in pH.  To examine any 
response to changes in pH on the structure of CACs, they were dispersed in solutions of 
pH 3, 5, 7, 9, and 11 and incubated for 4 weeks.  The solutions were prepared by 
combining deionized water, HCl (12 M) or NaOH (5M) to achieve the desired pH.  1 mL 
of a CAC suspension was placed in a dialysis membrane which was placed in a solution 
at the pH to be studied.  Capsules were removed from the dialysis membrane after each 
week for characterization.  Before making relaxation measurements capsules were 
washed twice with DI water to make sure that no influence on the relaxivity values is a 
contribution from the salts.  No apparent change in the size of the capsules was observed 
over four weeks at any pH studied (Figure 3.21).  Furthermore, SEM images show no 
notable change in capsules morphology over the same period. 
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Figure3.20: SEM images of CACs exposed to pH 3-11 from day 0 to day 28 for R = 0.3 
The per-Gd3+ relaxivity for CACs incubated between pH 3 and pH 9 remains essentially 
constant over the course of 4 weeks.  This suggests that in addition to the capsules 
retaining their shape and size, there is no appreciable release of the chelate or change in 
the protons (or water) transfer rate in the pH range 3-9.  In contrast, at pH 11, a 
continuous superlinear drop in relaxivity was observed for pH 11 over the course of the 
experiment.  Given the capsules do not seem to change size or shape significantly at this 
pH the most likely explanation for this drop in relaxivity is base catalysed hydrolysis of 
the Gd3+ ion from DOTP.  This would produce the insoluble Gd (OH)3(H2O)6 which 
would account for the drop in relaxivity. 
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Figure 3.21: A comparison of CAC% change in Gd3+ relaxivity and average size of 
capsules over 28 days at different pH values pH 3(red diamonds),pH 5 (orange 
diamonds), pH 7 (green triangles), pH 9(blue circles), pH 11(purple circles) and salts 
NaCl (blue circles), CaCl2 (green squares) and MgCl2 (red squares 
3.1.14: The effect of metal ions on CAC stability. 
In biological fluids several metal ions are abundant that may modulate the strength of 
electrostatic interactions.  To study whether some of the most abundant metal ions affect 
the function of CACs as MRI contrast agents, CACs were suspended in dialysis 
membranes in solutions of 5 mM CaCl2, 5 mM MgCl2 and 200 mM NaCl.  Ca2+ 
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accomplishes most of its biological process in the presence of Mg2+ so it was important to 
study both these ions on their effect on the CACs.  The experimental design was the same 
as that used for the pH.  CACs were suspended in dialysis membranes in solutions of the 
metal ion of interest.  The capsules were sampled each week during the 4 weeks of 
incubation in solutions of metal ions.  Capsule size was measured by DLS and the 
relaxation rate constants were measured at day 0 and each 7 days thereafter.  SEM images 
were taken (Figure 3.22) at the beginning and end of the incubation period to assess 
changes to the morphology of the capsules.  Size of the capsules was not affected by 
incubation in the presence of the endogenous metal ions Ca2+, Mg2+, and Na+.  
Furthermore, no change was observed in the relaxivity value of these capsules (Figure 
3.19).  This is of particular relevance in the case of Mg2+ and Ca2+, both of which are 
known to bind to GdDOTP5- and quenching relaxivity.  This suggests that the polymer 
hydrogen bonds to the phosphonate groups in such a way as to block the metal ion 
binding, which quenches relaxivity.  These salts also seem to have no effect on the 
electrostatics of the capsules, no disassembling of these capsules was observed based on 
the size analysis and the morphology studies using the SEM (Figure 3.22). 
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Figure 3.22: SEM images of CACs suspended in 5 mM CaCl2, MgCl2 and NaCl for day 
0 and day 28respectively 
MRI offers high spatial resolution, but in order to be used for molecular imaging 
applications it is necessary to deliver a high payload of Gd3+ to a specific pathology.  
CACs represent a solution to delivering high payloads of the Gd3+ chelates to the target 
site.  Moderately sized (≤ 30kDa) targeted contrast agents are often preferred because 
their small size enables them to diffuse freely to small areas and their simple clearance, 
but this type of targeted imaging tend to suffer low sensitivity with small Gd3+ based 
contrast agents.119, 120  Contrast agents that possess high relaxivity and the capability to 
deposit high payloads of contrast agents are more desirable from a detectability point of 
view.  This may limit the applications for which they can be used by their distribution 
characteristics but their use will not have the same detection limitations.  The 
development of such an agent may be envisioned through the attachment of a targeting 
moiety on the surface of the CAC.  A lot of work has been performed by conjugating 
targets112 and many other techniques which allows attachment of targeting moieties on 
the surface or link them to contrast agents.  Selective coupling of primary amino groups 
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to isothiocyanate is one of the methodologies which have been used under mild 
conditions.  To investigate whether it is possible to undertake such a coupling reaction on 
the surface of Gd3+ chelates containing CACs, a sample of the prepared R = 0.5 CACs 
where treated with FITC, an isothiocyanate was dissolved in DSMO at 1 mg/mL and was 
prepared fresh for each labelling and for every 1 mL of CACs, 50 µL of FITC solution 
was added.  CACs were suspended in 0.1 M sodium carbonate buffer at pH 9 and the 
buffer was prepared fresh, to make sure that pH of the buffer does not change upon 
storage.  Thorough washing was performed on the CACs to remove unreacted dye and 
CACs were imaged using a confocal microscope (Figure 3.23).  The intense green 
emission from the capsules indicates that FITC was able to access and react with primary 
amino groups on, or close to, the surface of capsules.  This shows that it should be 
possible to conjugate a targeting moiety on the surface of the CAC producing targeted 
high payload contrast agents with enhanced relaxivity.  Increasing the payload by 
synthesizing the CAC has shown to give high per-Gd3+ relaxivity values and 
incorporating many high relaxivity contrast agents in each capsule affords exceptionally 
high per-capsule relaxivities.  This means that each capsule will have very significant 
effects on water proton T1s reducing the detection limit of any agent targeted to a specific 
pathology of interest in molecular imaging applications.  We have also investigated the 
availability of primary amino functions on the surface of CACs with FITC to quantify the 
availability of these functional groups. 
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Figure 3.23:  Bright field optical field microscopy image of R = 0.5 CACs prepared with 
GdDOTP5- and treated with FITC after. 63xmagnification; excitation laser line 488 nm; 
excitation wavelength 500 nm; emission wavelength 555 nm; scan format 512 x 512 
pixels 
3.1.16 Conclusions 
A new method for robust encapsulating nano-assembled capsules has been developed.  
This method is tolerant of charge ratios (R) from 0.3 to 1.0, beyond a charge ratio of 1 
capsule were difficult to synthesize.  There was a stronger but similar relationship 
between the value of R and the size of capsules than for NACs.  The smallest capsules 
where obtained by using this alternative method of coating combined with a low R value.  
These very small capsules (127 nm) afforded the highest relaxivity values to date, almost 
twice as high as those of capsules coated with SiO2nanoparticles.  The interaction of 
GdDOTP5- with the cationic polymer limits the freedom of motion of the chelate and 
brings exchangeable protons into close contact with the chelate through the “second–
sphere”.121, 122  This is the origin of the enhanced relaxivity.  The alternative coating 
method allows movement of water molecules across the coating and does not have a 
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limiting effect on relaxivity.  The surface of CACs possess free amines which have been 
shown to be reactive to external labelling approaches, such as FITC a fluorescent agent as 
demonstrated by confocal microscopy.  The availability of reactive free amines on the 
surface of CACs is an added advantage of these capsules because they provide a method 
for attaching targeting moieties to the surface of these capsules.  The stability of CACs 
were also explored in this chapter for different metal ions (200 mM Na+, 5mM Ca2+ and 
5mM Mg2+) and pH values (3–11).  CACs were found to be robust in the presence of all 
of the metal ions studied for the duration of the four week experiment.  The relaxivity 
remained constant for four weeks and no detectable change in the size or morphology of 
the CACs was observed.  The effect of incubating CACs in solutions from pH 3–9 was 
found to be similar.  However, at pH 11 incubation has a substantial effect on relaxivity 
(presumably the result of metal hydrolysis) but the size and morphology of the CACs 
seem to be unaffected.  We can conclude that CACs are stable against many of the likely 
sources of interference from the constituents of extracellular fluids and represent good 
candidates for the development of high relaxivity, high payload molecular imaging 
agents.
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Chapter 4.  Synthesis of a reverse NAC as a paraCEST agent  
4.1. Introduction 
MRI is a clinical diagnostic method widely used in the medical field for anatomical 
imaging ,owing to its spatial and anatomical resolution.  Gd3+ complexes are widely used 
as MRI contrast agents in clinical diagnostic medicine.  These MRI agents lack tissue 
specificity and they do not respond to their chemical environment, therefore work has 
been performed where MRI contrast can be altered based on chemical exchange 
saturation transfer (CEST).  Paramagnetic metal complexes that can shift the frequency 
of an exchanging site in a chelate far from the bulk water signal may be able to function 
as a CEST agent.  Lanthanides ions such as Eu3+, Ho3+, Dy3+, Yb3+ and Tm3+ have near 
ideal properties as paramagnetic CEST agents.  Complexes formed from these ions and 
neutral ligands such as tetramides derivates of DOTA has the slower water exchange 
rates required of CEST agents.  Unlike Gd3+, these lanthanide metals have low relaxivity 
but when operating as paraCEST they maintain an ability to effect changes on image 
contrast123.  One of the major advantages of using paraCEST agents is the ability to turn 
them on and off by changing the pulse sequence parameters.  It is only when a pre-
saturation pulse is situated at the resonance frequency of the bound water molecule or 
exchangeable amides protons will the image exhibit CEST contrast.  A pre-saturation 
pulse at any other frequency will not affect the image.  And because these paraCEST 
agents have very low relaxivities they do not substantially alter the image through 
changes in T1 or T2.  This feature is unlike Gd3+ chelates which are always on and affect 
the image until the Gd3+ chelate has been cleared from the body.  This limits the timing of 
CHAPTER 4.  Preparation of Reverse NACs 73 
the acquisition of pre- and post-contrast images.  In molecular imaging applications it is 
envisioned that the post-contrast image will be acquired after administration of the 
contrast agent and after the agent has cleared from healthy tissue.  This will clearly be a 
long time after the acquisition of the pre-contrast image, creating problems for the co-
registration of the two images.  A contrast agent, such as paraCEST agent, that can be 
switched on and off will offer a significant advantage because the pre- and post-contrast 
images can be collected one after the other faciltating better co-registration of the images. 
One of the major limitations of CEST is the inherent sensitivity of paraCEST agents.  
However, entrapping paraCEST agents in nano-scale capsules could deliver a large 
payload of a paraCEST agent and improve the limit of detection for these agents.  This 
opened new avenues for the discovery of new classes of responsive agents like MR gene 
reporters to small molecules that respond to biological events.  Since the first 
demonstration of paraCEST contrast agents by Zhang and his co workers in 200182, they 
have been explored for a number of biomedical applications for different targets pH72, 124, 
temperature125, 126, enzymes127, 128, metabolites129-131 and metal ions.132, 133  Use of 
paraCEST contrast agents have shown promise in in vivo system application.  The biggest 
challenge of paraCEST contrast agents method in in vivo is loss of sensitivity and poor 
temporal resolution for detection, due to magnetization transfer from endogenous 
macromolecules following application of radio frequency pulse that saturates bulk water 
spins lowering the contrast efficiency of ParaCEST agents.  Currently available 
ParaCEST agents are inherently insensitive as imaging agents, therefore they require 
agents in the millimolar range.  A number of approaches for increasing the proton or 
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water exchange rates and the number of exchangeable groups per agent, and the latter 
approach seems to be more promising87, 134, 135, therefore incooperation of contrast agents 
into nano assembled capsules is another way to increase contrast agent localization, it is a 
more effective way to increase contrast agent molecules to a region with highly loaded 
capsules with the contrast agent.  There are a number of nanoparticle strategies that have 
been investigated to enhance the sensitivity of CEST contrast agents.  Entrapment of 
CEST contrast agents involves binding the CEST agent to the nanoparticle structure 
physically or trapping the contrast agent and chemically attaching a CEST agent both 
diaCEST and ParaCEST agents have been demonstrated to be trapped using polymers136-
138, liposomes111, 139 and dendrimers87, 140 and where able to generate a CEST effect.  In 
this chapter we investigated one system where we synthesized a reverse NAC by 
incorperating a traditional ParaCEST DyDOTAM3+. 
 
Scheme 6: The structure of the chelate used in the synthesis of the reverse NACs 
4.2: Experimental 
4.2.1: General remarks 
A solution of polyacrylic acid (100,00 MW acrylic units per molecule, 35 wt % in water) 
and poly allyamine hydrochloride (56, 000 MW ~ 596 allylamine units per molecule) 
were purchase at sigma Aldrich.  Ethylene diamine (EDA) was purchased from J.T 
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Baker.  A suspension of SiO2 NP (Snowtex-O type, 20.3 wt % SiO2 NP, and pH 3.5 was 
purchased from Nissan chemicals and the pH adjusted to 5.5 using 150 mM NaOH prior 
to use.  Deionized water (18.2 MΩ, Barnstead Nanopure Diamond System) was used in 
all reactions 
4.2.2: Reverse NAC synthesis 
An aqueous solution of PAA (215 𝜇L, 5 mg/mL) was mixed with an aqueous 
DyDOTAM3+ solution (535 𝜇L, 40 mM) in a 1.5 mL eppendorf centrifuge tube and 
vortex mixed for 10 seconds at low speed.  A charge ratio R = 0.5 (equation 2.1) was 
studied in this work, the EDA concentration was 0.11 M.  A turbid mixture immediately 
resulted, indicating the formation of PAA-DyDOTAM aggregates the reaction mixture 
was vortexed at a very low speed for 5 seconds and aged for 10 seconds, and an aqueous 
solution of PAH (20 µL, 89 µM) was added to the turbid solution of PAA-DyDOTAM 
aggregates and vortexed at a low speed for 10 seconds and aged for 15 seconds.  EDA 
was added (215 µ𝐿) to the turbid solution and there was an increase in turbidity.  This 
suspension was aged for 10 seconds, before an aqueous SiO2NPs suspension (535 𝜇L; 
concentration of 2.0 wt %) was added.  The resultant mixture was stirred vigorously at a 
medium speed for 10 seconds and aged for 2 hrs.  Unreacted starting materials were 
removed by filter centrifugation using 10 kDa MWCO filter centrifuge tube.  
4.3: Results and Discussion 
It has been successfully shown in our earlier work that NACs are a versatile platform for 
the development of high payload contrast agents.  However, assembly had previously 
been limited to a cationic polymer, multivalent anionic contrast agents, and negatively 
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charged NPs.  We wondered whether NAC synthesis could be made in a reverse 
assembly methodology, comprising an anionic polymer, multivalent cationic contrast 
agents, and negatively charged NPs.  The motivation for this reversal is the possibility to 
incorporate a positively charged paraCEST contrast agent into the capsule.  For this 
reason Gd3+ is replaced by Dy3+, because Dy3+ has near ideal properties as a 
paramagnetic CEST agent when chelated with a neutral ligand such as DOTAM.  Dy3+ 
significantly shifts the amide protons of the ligand which are in slow exchange with 
water; however, once inside a capsule it is not clear that this chelate will continue to 
function as a CEST agent since the rate at which protons exchange may change due to 
hydrogen bonding interactions.  However, if exchange remains in the slow regime then 
the concept of reverse assembly may facilitate a method by which high loadings of 
positively charged chelates can be achieved.  In addition to high payloads of CEST agent, 
one other approach to increasing the sensitivity of CEST is to increase the number of 
exchangeable protons per agent.  For this reason DyDOTAM3+ was chosen as the CEST 
agent.  In addition to 2 exchanging water protons shifted to -760 ppm, this chelate has 8 
amide protons that can exchange slowly with water shifted to +90 ppm.  To achieve the 
reverse NAC synthesis DyDOTAM3+ was mixed with the anionic polymer polyacrylic 
acid (PAA) in an aqueous solution and PAA at pH of 7.  Upon mixing the solution 
rapidly went turbid, a strong indication of aggregate formation.  Encapsulating this 
aggregate proved more challenging because the aggregate surface is predominantly 
negatively charged as are SiO2NPs.  For this reason initial attempts at encapsulation were 
performed using EDC and polyamines in an attempt to cross-link the capsule shell (c.f. 
Chapter 3).  However, this approach, while theoretically viable, currently remains 
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unsuccessful.  An alternative strategy was therefore pursued in which the aggregate 
surface was charge modified prior to addition of SiO2NPs.  A solution of the cationic 
PAH was added to the aggregates after 10 seconds of aging followed by ethylene diamine 
and aggregates aged for 10 seconds before SiO2NPs were added to encapsulate the, now 
positively charged, aggregate.  Spherical capsules were formed which appear similar by 
SEM to those formed using PAH and anionic chelates (Figure 4.24).  The size of capsules 
was measured using dynamic light scattering and was found to be 650 ± 250 nm.  These 
reverse NACs are much larger than the NACs prepared using PAH and anionic chelates 
at the same charge ratio NACs.  For example, NACs prepared with the trianionic chelate 
GdTTHA3- had an average size of 180 nm, less than a third of the size of the650 nm 
determined for the reverse capsules.  It is speculated that this difference arises from 
differences in the strength of the interaction of the anion and cation in the aggregate, the 
additional polymer layer than needed to be added and a difference in the interaction of 
the SiO2NPs with this additional polymer layer, versus the PAH of the aggregates in the 
NACs. 
 
Figure 4.24: SEM images for reverse NACs for DyDOTAM/PAA for R = 0.5 
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Figure 4.25: CEST spectra of 40 mM DyDOTAM chelate solution (red circles) and 40 
mM DyDOTAM NACs (blue circles) 
The CEST spectrum of DyDOTAM3+ is shown in Figure 4.25.  A CEST peak arising 
from DyDOTAM3+ is clearly visible at +90 ppm from the bulk water, which is known to 
arise from the 8 amide protons.  However, the CEST spectrum of DyDOTAM3+ 
containing reverse NACs shows no CEST peak at all in this part of the spectrum.  This 
disappointing result may have several causes: T1/T2, concetration, acceleration of 
exchange beyond the slow exchange regime, inihibition of exchange by aggregate 
formation.  In these experiments CEST from the bound water molecule at -760 ppm was 
not investigated.  However, going forward this is an important factor to investigate since 
one may envision amide protons interacting directly with the PAA of the aggregate.  In 
contrast, the bound water may have no direct interaction at all and its CEST properties 
may be largely unaffected by encapsulation it was difficult to observe a CEST signal for 
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encapsulated DyDOTAM3+ NACs at this chemical shift.  We speculated that 
encapsulation of this chelate reduces rotational correlation time and lengthens R1 and R2 
this has a consequence that direct saturation of the water protons surpasses the CEST 
effect, hence we did not observe a CEST signal from these reverse NACs. 
4.5: Conclusions 
A novel approach was developed to synthesize reverse NACs containing paraCEST 
agents and CEST data was acquired to assess the effect of encapsulation.  No observable 
CEST was observed from the amide protons of DyDOTAM3+ upon encapsulation of the 
chelates.  We speculate that as we encapsulate the chelate there is an increase in exchange 
rate and it increased a maximum and ∆𝜔 begins to broaden and decrease and the 
exchange peak shifts towards the bulk water frequency (0 ppm).  This causes the CEST 
signal to disappear completely when the exchange is too fast hence no observable 
difference between the bound and bulk water protons can be observed.  There is still a lot 
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